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SUMMARY 
 
The human Plasmodium falciparum (P.falciparum) parasite, currently infects more than 
200 million people annually, causing about 500 000 deaths a year and imposes 
considerable morbidity on the surviving population. Since 2001, the WHO has 
recommended Artemisinin based combination therapies (ACTs) as treatment of choice 
for falciparum malaria. However the WHO has observed foci of suspected artemisinin 
resistance in South- east Asia. Because strains of P. falciparum are rapidly emerging 
that are resistant to all known antimalarial drugs, including artemisinin, quinine, 
chloroquine, piperaquine, and mefloquine and their derivatives, emphasis is currently 
laid on comprehension of new therapies with novel mechanisms of action that includes 
also the patient’s immune response. 
Delayed parasite clearance (DPC) has been identified as an useful indicator of artemisin 
resistance but it has been shown that parasite clearance suffers interindividual 
variability and reactivity to antimalarials may depend on host immunity.  
Recently, studies have demonstrated Syk Inhibitors (R406) as potentially useful new 
class of antimalarial drugs reducing parasitemia by two ways i) delaying P.falciparum 
growth and ii) suppressing merozoite egress. The latter is caused by interfering of Syk 
inhibitors with the membrane of the parasite harboring host RBC.  
Aim of this study is to understand whether the efficacy of new antimalarial 
combinations of Syk inhibitors and artemisinins (ARTs) is paralleled by enhanced 
immune responses of the host. I tried to identify a role of antimalarial drug treatment in 
the parasites clearance by host’s innate immunity. To reach the goal, I studied the 
activating effect of Syk inhibitor R406, dihydroartemisinin (DHA) and the combination 
of both on cellular immune functions in in vitro experiments with human monocytes. 
First line defense mechanism against the malaria parasite, such as phagocytosis and 
oxidative burst were assessed in cultured primary phagocytes using ring-stage 
parasitized RBC as phagocytosis target without and with previous DHA and R406 
treatment. The molecular basis for observed functional changes was investigated 
studying DHA- and R406-dependent opsonin-binding to ring-stage pRBCs. by flow 
cytometry, Western blotting and immune-precipitation.  
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Monocytes show an increased phagocytosis level after treatment of parasitized Ring-
PRBC with DHA and R406 and highest phagocytosis values when DHA and R406 were 
supplemented together at concentrations of 0.1uM and 0.5 uM, respectively. 
Membrane-bound autologous IgG and C3c complement factor were remarkably 
increased on Ring-PRBC surface after treatment with DHA and R406 as judged by flow 
cytometry. Immunoprecipitation confirmed Band 3 as main protein that is labelled by 
IgG in Syk-inhibitor treated pRBC and the decreased IgG/band 3 ratio in treated cells 
vs. untreated ones supports the band 3 aggregation model as signal for IgG flagging. 
Enhanced phagocytosis of PRBCs may represent the common mechanism for innate 
malaria protection in nonimmune individuals. Modifications on band 3 of host cell 
membranes accumulate by the oxidative challenge of the growing parasite accompanied 
by binding of haemichromes to the cytoplasmic tail of band 3. At the moment when a 
threshold of modifications is exceeded mainly at trophozoite stage PRBC are 
recognized by phagocytes and ingested. We hypothesize Syk kinase inhibitors to 
anticipate the moment of recognition by an early accumulation of modified band 3 and 
bound haemichromes already at ring stage. Syk inhibitors are described to specifically 
inhib phosphorylation used by PRBC to shed off band 3 –rich microparticles from their 
membrane.  Consequently, DHA as radical producing molecule enhances the oxidative 
challenge in PRBC.  
In conclusion, my data support the hypothesis that Syk inhibitors are a promising class 
of antimalarial drugs that can suppress parasitemia by increasing also the antiparasitic 
immune defense. Particularly, R406 should not lead to the selection of resistant strains, 
as it targets host cell molecules and will likely avoid immunosuppressive effects of 
hemozoin due to the anticipated phagocytosis of Ring stage-PRBC. Therefore, Syk 
inhibitors may represent a strategic partner drug for artemisinin therapies for 
counteracting artemisinin resistance. 
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1.1 Background and epidemiology of Malaria 
 
Malaria is a parasitic disease caused by a protozoa hemosporidae belonging to the genus 
of plasmodium. This infective disease is transmitted by the bite of female Anopheles 
mosquito, which lives mainly in the region with temperate to hot climate. Among all 
studied mosquitoes species, only few of them are responsible for malaria disease in men, 
whereas the others are harmless, as they prefer animal blood compared to human blood. 
The main vector responsible for malaria in the Afrotropical region is 
Anopheles Gambiae specie (Fig.1). 
 
 
                 Fig. 1. Female Anopheles mosquito 
 
In the past few years, the disease has spread again through the western African continent 
even though it has been eradicated in these regions few years ago. The migrant’s fluxes 
have been claimed as a possible cause of this unexpected event.  
Malaria is an infective disease whose severe courses cause a high level of deaths in the 
world. According the 2018 WHO Malaria report 219 million cases of malaria. and 435 
000 deaths from malaria were estimated globally. This high incidence of mortality is 
due to the considerable percentage of population, particularly in rural remote areas, 
without access to prompt diagnosis and effective treatment of malaria. More than 77% 
of children with severe cerebral malaria and convulsion die under 5 years of age, for 
this reason malaria is also known as “disease of childhood” [1]. The sub-Saharan region 
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is the most malaria endemic area, infact, WHO African Region accounted for 93% of 
all malaria deaths in 2017. Although the WHO African Region was home to the highest 
number of malaria deaths in 2017, it also accounted for 88% of the 172 000 fewer global 
malaria deaths reported in 2017 compared with 2010.  
In Italy 3600 cases of malaria have been registered in the period 2011-2016 mainly due 
to the migratory fluxes.  
Although the number of Plasmodium falciparum malaria cases has rapidly decreased in 
the last five years [2], malaria remains one of the most devastating infectious diseases 
in the world, thereby the main effort consists in eradicating it. 
This disease is endemic in 103 nations therefore many people are exposed to this kind 
of pathology. Malaria affects also pregnant women and infants, who encounter the 
pathology directly from the mother, through blood exchange [3,4].  
Annually around 100 thousand of infants die for malaria infected from their mother [5] 
and 25 million of pregnant women are at risk of infection around the world [6]. 
Exist five protozoa species able to cause Malaria in humans all belonging to 
Plasmodium (P.) genus: 
 
1. P. falciparum 
2. P. vivax 
3. P. ovale 
4. P. malariae 
5. P. knowlesi (humans and macaques) 
 
These species of Plasmodium cause different malaria pathologies and it is important to 
differentiate them due to differences in mortality, incidence and distribution. 
Among the Plasmodium species, two are most important for clinical and severe malaria, 
P. vivax (endemic region) and P. falciparum (Africa, Asia, Latin America). Plasmodium 
falciparum represents the most pathogenic [7] with the highest rates of complications 
and mortality [8] 
It is the most prevalent malaria parasite in the WHO African Region, accounting for 
99.7% of estimated malaria cases in 2017, as well as in the WHO regions of South-East 
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Asia (62.8%), the Eastern Mediterranean (69%) and the Western Pacific (71.9%). P. 
vivax is the predominant parasite in the WHO Region of the Americas, representing 
74.1% of malaria cases. 
The immune system plays an important role in the defense against illness. The first time 
that our organism has contact with an infective agent is crucial, dangerous and 
potentially harmful, because the appropriate immune response is not yet prepared to 
prevent the infection. For this reason, people who are physiologically 
immunosuppressed such as kids are more prone to die. Next chapter are going to 
describe life cycle, pathophysiology and diagnosis of Malaria.  
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1.1.1 Life cycle of Malaria parasite  
 
The malaria parasite life cycle involves two hosts. As shown in figure 3, during a blood 
meal, a malaria-infected female Anopheles mosquito inoculates sporozoites into the 
human host (1). The sporozoites infect liver cells (2) and mature into schizonts (3), with 
consequent rupture of membrane and release of merozoites (4). In P. vivax and P. ovale 
a dormant stage [hypnozoites] can persist in the liver and cause relapses by invading 
the bloodstream weeks, or even years later. 
After this initial replication in the liver (exo-erythrocytic schizogony (A)), the parasites 
undergo asexual multiplication in the erythrocytes (erythrocytic schizogony (B)). 
Merozoites infect red blood cells (5). The ring stage (1-24 hours) and trophozoites (24-
36 hours) mature into schizonts (36-48 hours), with lysis of red blood cells (RBCs) 
membrane (Fig.2) and release of merozoites (6) to further infect red blood cells.  Blood 
stage parasites are accountable for the clinical manifestations of the disease. 
During the erythrocytic cycle some parasites differentiate into sexual erythrocytic 
stages (gametocytes) (7). 
 
Fig. 2. Intraerythrocytic cycle of parasite 
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The gametocytes, male (microgametocytes) and female (macrogametocytes), are 
ingested by an Anopheles mosquito during a blood meal (8). The parasites’ fertilization 
and proliferation in the mosquito is known as the sporogonic cycle (C). In the 
mosquito’s stomach, the microgametes penetrate the macrogametes generating zygotes 
9. The zygotes in turn become motile and elongated (ookinetes) 10 which invade the 
midgut wall of the mosquito where they develop into oocysts 11. The oocysts grow, 
rupture, and release sporozoites 12, which make their way to the mosquito’s salivary 
glands. Inoculation of the sporozoites 1 into a new human host perpetuates the malaria 
life cycle (Fig.3) [9] 
 
 
 
Fig. 3. Sexual and asexual life cycle of plasmodium 
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The activation of parasite metabolic processes inside the RBCs, triggers alterations of 
host cell energetic metabolism, proteins and membrane structural changes. An example 
of functional importance for P. falciparum- induced changes of the infected RBC is the 
expression of proteins on the erythrocytes external surface that mediate the infected 
RBCs process of adhesion to the endothelial cells in capillaries of some organs. 
This phenomenon, known as “adhesion”, represents an essential pathogenic mechanism 
in P. falciparum severe malaria and avoids spleen passages of the mature parasite and 
its phagocytic removal. Malaria parasites degrade host cell haemoglobin (hereafter 
referred to as Hb) as amino acid source for protein synthesis in the intraerythrocytic 
stage, during which the heme group is converted to hemozoin (hereafter referred to as 
Hz), which is essential for parasite survival [10]. Mature trophozoites digest 
haemoglobin and metabolize glucose, through the anaerobic glycolysis. An infected 
RBC increases of 50 - 100 fold the consumption of glucose with the production of lactic 
acid compared to uninfected red blood cells. The degradation of Hb occurs in a 
specialized parasite organelle called the food vacuole. Previously studies have 
suggested that Hb degradation is a cooperative process that involves proteases of 
multiple catalytic classes, including cysteine, aspartic, and metalloproteases [11]. These 
proteases produce short peptides that are further degraded to amino acids, probably by 
aminopeptidases [12]. During the process of Hb degradation, heme groups released in 
the food vacuole is toxic to Plasmodium, as it induces oxygen-derived free radical 
formation, lipid peroxidation and protein and DNA oxidation. Organisms such as 
Plasmodium, Schistosoma, and Rhodnius, which use Hb as a nutrient source, have 
evolved different strategies to detoxify free heme. Plasmodium spp. converts the heme 
group to β-hematin, which is a dark brown core of malarial pigment also known as Hz, 
through a process that is essential for the life cycle of these organisms [13,14]. The beta-
hematin core of HZ is a cyclic dimer of ferriprotoporphyrin IX [Fe(III)PPIX] in which 
the propionate group of each Fe(III)PPIX molecule coordinates the Fe(III) centre of its 
partner. Dimers form chains linked by hydrogen bonds in the beta-hematin crystal [14]. 
The formation of mature schizonts containing a variable number of merozoites (24-32), 
entails their release and the lysis of erythrocytes. This process occurs every 48h 
corresponding with the parasite life cycle. During this event, the first clinic symptoms 
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of the disease are shown: the characteristic fever ‘malignant tertian’ in P. falciparum, 
‘benign tertian’ in P. vivax and P. ovale and ‘quartan’ in P. malariae (Fig 4).  
 
 
Fig. 4. Fever cycle in in different kind of plasmodium 
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1.2 Diagnosis of malaria 
 
The signs and symptoms of malaria are similar to those of many other febrile illnesses. 
In non-immune individuals, malaria typically presents with fever, sometimes 
accompanied by chills, sweats, headache or other symptoms that may resemble other 
illnesses. Consequently, fever is the main basis for suspicion of malaria, and a trigger 
for diagnostic testing of the patient in most malaria endemic settings. No combination 
of signs or symptoms that reliably distinguishes malaria from other causes of fever 
exists. For this reason, in malaria-endemic areas, malaria should be suspected in an 
patient presenting with a history of fever or temperature of 37°C and no other obvious 
cause. In areas in which malaria transmission is stable, malaria should also be suspected 
in children with palmar pallor or a haemoglobin concentration of <8 g/dL. In settings 
where the incidence of malaria is low, health workers should be trained to identify 
patients who may have been exposed to malaria. In all cases, patients with suspected 
malaria should have prompt parasitological confirmation of diagnosis, with either 
microscopy or rapid diagnostic tests (RDT), before antimalarial treatment is started.  
Depending on the malaria parasites, it may be present a variety of symptoms [13], 
ranging from absent or very mild symptoms to severe disease and even death. For this 
reason, malaria disease can be classified as uncomplicated or complicated (severe) [14]. 
 
1.2.1 Uncomplicated malaria 
 
The classical malaria attack lasts 6-10 hours. It consists of a series of events: a cold 
stage (sensation of cold), hot stage (fever, headaches, vomiting), and finally a sweating 
stage (sweats, return to normal temperature). Usually attacks occur every second day 
with the “tertian” parasites (P. falciparum, P. vivax and P. ovale) and every third day 
with the “quartan” parasite (P. malariae). More commonly, the patient presents a 
combination of the following symptoms: fever, chills, sweats, headaches, nausea and 
vomiting.  
 
  19 
 
1.2.2 Severe malaria 
 
Severe malaria occurs when infections are complicated by serious organ failures or 
abnormalities in the patient’s blood or metabolism [15].  Most of the severe malaria 
complications occur in non-immune subjects with falciparum malaria and involve 
central nervous system (cerebral malaria), pulmonary system (respiratory failure), renal 
system (acute renal failure) and/or hematopoietic system (severe anaemia) [14]. 
These complications can be rapid and considering that severe malaria is a potentially 
fatal disease, any patient with malaria symptoms must be assessed and treated rapidly. 
The patients also, must be kept under observation to identify early signs of systemic 
complications. 
A parasitological diagnosis should be obtained whenever possible, but the relevance of 
parasitaemia to the current illness must always be considered carefully. In the absence 
of diagnostic facilities, antimalarial treatment should not be delayed if the patient is 
severely ill.  
The manifestations of severe malaria include: 
1. Cerebral malaria, with abnormal behaviour, impairment of consciousness, 
seizures, coma, or other neurologic abnormalities 
2. Severe anaemia due to haemolysis (destruction of the red blood cells) 
3. Haemoglobinuria (haemoglobin in the urine) due to haemolysis 
4. Acute respiratory distress syndrome (ARDS), an inflammatory reaction in the 
lungs that inhibits oxygen exchange, which may occur even after the parasite 
counts have decreased in response to treatment 
5. Abnormalities in blood coagulation 
6. Low blood pressure caused by cardiovascular collapse 
7. Acute kidney failure 
8. Hyperparasitemia, where more than 5% of the red blood cells are infected by 
malaria parasites 
9. Metabolic acidosis (excessive acidity in the blood and tissue fluids), often in 
association with hypoglycaemia 
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10. Hypoglycaemia (low blood glucose). Hypoglycaemia may also occur in pregnant 
women with uncomplicated malaria, or after treatment with quinine. 
 
1.2.3 Cerebral Malaria 
 
Despite decades of research, cerebral malaria remains one of the most serious 
complications of Plasmodium infection [16]. If left untreated, cerebral malaria is 
probably nearly always fatal. Even when treated, cerebral malaria has an approximate 
20% of mortality rate in adults and 15% in children. Among subjects who survive, the 
recovery is relatively rapid with complete reversibility of neurological signs and 
symptoms.  
Erythrocytes infected by parasite in the microcirculation, especially the cerebral one 
have a tendency to accumulate, based on plasmodium antigens present on the RBC 
surface that bind to endothelial receptors and to form rosettes with non-parasitized RBC 
causing the formation of clots, blocking the bloodstream.  
This process is not a classic thrombosis, because is caused by infected RBCs. Since the 
brain and the hematic microcirculation cannot be infected, immediately the immune 
system induces an acute inflammatory response leading to a degeneration of cerebral 
tissue. The process involves the release of the cerebral TNF and INF-γ, causing the 
increase of fever and definitely the death. The overwhelming cytokine release is likely 
due to the release of hemozoin during rupture of schizonts adhered to endothelia. 
Hemozoin has been shown to be a very potent short-term activator of pro-inflammatory 
responses, such as ROS production and pro-inflammatory cytokine release, such as 
TNF or MCP-1.  
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1.3 Erythrocytes plasmatic membrane 
 
The RBCs plasmatic membrane is constituted of 50% protein (mainly intrinsic), 40% 
lipids and 10% carbohydrates. The erythrocyte is different from the other cells since the 
cytoskeleton forms a shell to support the plasmatic membrane. 
Red blood cells plasmatic membrane structure 
Protein Band 3 (Anion Exchanger 1) is the main protein (25%) in the red blood cells 
membrane, involved in different cell process. Its molecular weight is 95 KDa and it can 
exist in monomeric, dimeric, tetrameric form or aggregates [17]. In the red blood cells, 
the Band 3 mediates the anionic exchange between the bicarbonate ion (HCO3-) 
presents in cytoplasm and ion chloride (Cl-) presents in the plasma (Fig. 5). 
The bicarbonate ion is involved in the following reaction catalysed from the carbonic 
anhydrase. 
CO2 +H2O  H2CO3  H+ + HCO3 – 
The presence of bicarbonate ion activates Band 3 that through an anion exchange allows 
the diffusion of chloride ion (chloride shift). Exported bicarbonate leaves a proton ‘in 
excess’ behind which decreases the cytoplasma pH. Acidic cytoplasm decrease the 
affinity between haemoglobin and oxygen in order to facilitate the transfer of it to the 
tissues.  
 
Fig.5 Schematic showing the exchange of bicarbonate (HCO3¯) and chloride (Cl¯) ions via AE1 
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Band 3, being the most abundant protein in the erythrocyte plasma membrane do not 
work only as anionic exchange, but also serves as a protein anchor, connecting the 
soluble cytoplasmic proteins and components of the cytoskeleton to the membrane. 
[18]. 
The protein Band 3 (Fig. 6) is composed of a transmembrane domain and two 
cytoplasmic domains [19]. Each protein domain has precise and different cellular 
functions: 
- The transmembrane hydrophobic domain is a region of 52KDa and includes 
the amino acid residues 360-878. It is dipped in the bilayer of phospholipids forming a 
series of 12-14 foldings. This domain lead to the formation of an anionic channel that 
allows the exchange of Cl - against HCO3 – between the external and internal of cell.  
- The N-terminal hydrophilic domain (cytoplasmic domain) of 43KDa, includes 
the amino acid residues 1-359, known as cytosolic domain of Band 3 (cdb3). It 
penetrates in the cytosol playing a role for anchorage of the cytoskeleton and several 
cytosolic proteins such as haemoglobin and aldolase. but also Ankyrin, Band 4.1 and 
4.2 that define the erythrocyte shape. At the N-terminal domain can bind different kind 
of proteins including the ankyrin and Band 4.1 and 4.2 that characterize the erythrocyte 
shape.   
- The C-terminal hydrophilic domain includes the last 33 aminoacidic residues 
directed towards the cytoplasm. 
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Fig. 6. Model of human erythrocyte band 3. The protein contains 2 
structurally and functionally distinct domains: a cytoplasmic binding 
domain (amino acids 1-359) and a transmembrane domain (amino acids 
360-878) that forms the anion-exchange channel 
 
The cytoskeleton is constituted of the Ankyrin complex and Actin junctional complex 
(Fig.7). The cytoskeletal proteins are situated in the internal surface of erythrocyte 
membrane and it forms a fibrillar skeleton with the function of holding the red blood 
cell structure.  
The Ankyrin protein binds Band 3 to high molecular weight proteins as α and β 
spectrins, belonging to the erythrocytes membrane [20]. These proteins create few 
anchorage points between the β subunit of spectrin and the integral proteins of 
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membrane as Band 3 and glycophorin. The spectrin dimers associate in tetramers, 
forming with other proteins as actin, adducin, 4.9 and 4.1 protein and tropomyosin, a 
fibrillary net that contribute to stabilize the erythrocytes structure. Furthermore, three 
other proteins are present in the junctional complex, namely adducin, P55 and dematin 
[21,22]. 
 
 
 
 
Fig. 7. Ankyrin and Actin junctional complex representation 
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1.4 Treatment of Malaria 
 
The World Health Organization (WHO) is annually publishing guidelines for the 
treatment of Malaria. The primary objective of treatment is to ensure complete cure that 
is the rapid and full elimination of the Plasmodium parasite from the patient’s blood, in 
order to prevent progression of uncomplicated malaria to severe disease or death, and 
to chronic infection that leads to malaria-related anemia [23]. 
The principal core for the treatment of Malaria according with guidelines of WHO are: 
Early diagnosis and prompt effective treatment of malaria.  
Uncomplicated falciparum malaria can progress rapidly to severe forms of the disease, 
especially in people with no or low immunity, and severe falciparum malaria is almost 
always fatal without treatment. Therefore, programs should ensure access to early 
diagnosis and prompt, effective treatment of malaria within 24-48h of onset of 
symptoms.  
Rational use of antimalarial agents 
To reduce the spread of drug resistance, limit unnecessary use of antimalarial drugs and 
better identify other febrile illnesses in the context of changing malaria epidemiology, 
antimalarial medicines should be administered only to patients who truly have Malaria. 
Adherence to a foul treatment course must be promoted. 
Combination therapy 
Preventing or delaying resistance is essential for the success of both national and global 
strategies for control and eventual elimination of Malaria. To help protect current and 
future antimalarial medicines all episodes of malaria should be treated with at least two 
effective antimalarial medicines with different mechanisms of action (combination 
therapy). 
 
 
  26 
 
Appropriate weight-based dosing 
To prolong their useful therapeutic life and ensure that all patients have an equal chance 
of being cure, the quality of antimalarial drugs must be ensure and antimalarial drugs 
must be given at optimal dosages. Treatment should maximize the likelihood of rapid 
clinical and parasitological cure and minimize transmission from the treated infection. 
To achieve this, dosage should be based on the patient weight and should provide 
effective concentrations of antimalarial drugs for a sufficient time to eliminate the 
infection in all target population. 
 
Treating uncomplicated P.falciparum malaria.  
Following guidelines of WHO is appropriate treat children and adults with 
uncomplicated P. falciparum malaria (expect pregnant women in their first semester) 
with one of the following recommended artemisinin-based combination therapies 
(ACT): 
Artemether + Lumefantrine 
Artesunate + Amodiaquine 
Artesunate + Mefloquine 
Dihydroartemisinin + Piperaquine 
Artesunate + Sulfadoxine-Pyrimethamine 
ACT regimens should provide 3 days treatment with an artemisinin derivative. Children 
< 25kg treated with Dihydroartemisinin + piperaquine should receive a minimum of 2.5 
mg/Kg body weight (bw) per day of Dihydroartemisinin and 20mg/kg bw per day of 
piperaquine daily for 3 days ]23]. In low transmission areas, give a single dose of 
0.25mg/kg bw primaquine with ACT to patients with P.falciparum malaria (expect 
pregnant woman, infants aged < 6 months and women breastfeeding infants aged < 6 
months) to reduce transmission. Testing for glucose-6-phosphate dehydrogenase 
(G6PD) deficiency is not required.  
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Treating uncomplicated P.vivax, P. ovale, P. malariae, P. knowlesi malaria.  
Following good practice statement, if the malaria species is not known with certainty, 
treat as for uncomplicated P.falciparum malaria.  
In areas with chloroquine-susceptible infections, treat adults and children with 
uncomplicated P.vivax, P. ovale, P. malariae or P. knowlesi malaria with either ACT 
(expect pregnant women in their first trimester) or chloroquine. 
In areas with chloroquine-resistant infections, treat adults and children with 
uncomplicated P.Vivax, P. ovale, P. malariae or P. knowlesi malaria with either ACT 
malaria (expect pregnant women in their first trimester) with ACT. Treat pregnant 
women in their first trimester who have chloroquine- resistant P.vivax malaria with 
quinine. 
 
1.4.1 Artemisinin and artemisinin derivates. 
 
The discovery of artemisinin for malaria therapy by Chinese scientists in the 1970s was 
one of the greatest discoveries in medicine in the 20th Century [24]. The project leading 
to the discovery of artemisinin was initiated in response to a request from North 
Vietnamese leaders suffering heavy losses of soldiers due to malaria during the Vietnam 
War. 
Artemisinin is isolated from the plant Artemisia annua (Fig. 8), sweet wormwood, an 
herb employed in Chinese traditional medicine. The drug was brought into modern 
medicine by Tu Youyou. For her discoveries, Tu received the 2015 Nobel Prize for 
Physiology or Medicine.  
 
Fig. 8. Artemisia Annua 
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From Tu’s discovery, Artemisinin (ART) and its semi-synthetic derivates, are a group 
of drugs used against P. falciparum malaria [25]. Treatments containing an artemisinin 
derivates actually represent the standard therapies worldwide for P. falciparum.  
Chemically, artemisinin is a sesquiterpene lactone containing an unusual peroxide 
bridge. This peroxide (Fig.9) is believed to be responsible for the drug’s mechanism of 
action. Because the parent drug of artemisinin is poorly soluble in water or oil, the 
carbonyl group of artemisinin was reduced to obtain DHA and its derivatives such as 
the water-soluble artesunate and oil-soluble artemether and arteether, which also show 
greater antimalarial activity. Few other natural compounds with such a peroxide bridge 
are known [26]. 
 
Fig. 9 Artemisinin (ART), dihydroartemisinin (DHA) and its derivatives arteether, artemether and artesunate, 
artemisone.  
 
Therapies that combine artemisinin or its derivatives with some other antimalarial drug 
are the preferred treatment for malaria and are both effective and well tolerated in 
patients.  
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Mode of action & potential cellular targets 
The mechanism of action of artemisinins is not known. Despite tremendous research 
efforts on artemisinin since its discovery, there is still considerable debate concerning 
its mode of action on malaria parasites. Artemisinins are considered prodrugs that are 
activated to generate carbon-centered free radicals or reactive oxygen species (ROS). 
As peroxides are known sources of ROS, earlier studies suggest that artemisinins 
modulate parasite oxidative stress and reduce the levels of antioxidants and glutathione 
(GSH) in the parasite.  Thus, the most widely accepted theory is that they are first 
activated through cleavage after reacting with heme and iron (II) oxide, which results 
in the generation of free radicals that in turn damage susceptible proteins, resulting in 
the death of the parasite [27,28].  
Another hypothetical mechanism considers the heme as target of drug action. Heme, 
generated from digestion of hemoglobin in the food vacuole of the parasite, is toxic to 
the parasite and must be detoxified through polymerization to form ‘hemozoin’ (malaria 
pigment) [29]. Artemisinin-derived radicals readily react with free hemin, heme present 
in the hemozoin and hemoglobin to form heme–artemisinin adducts in vitro. These 
adducts can be isolated from P. falciparum culture and Plasmodium vinckei-infected 
mice after artemisinin treatment. Similar heme adducts are observed with synthetic 
antimalarial trioxanes, suggesting an analogous mode of action for these compounds. 
In 2016 artemisinin was shown to bind to a large number of targets suggesting that it 
acts in a promiscuous manner [30]. 
 
Dihydroartemisinin (DHA) 
Because the physical properties of artemisinin itself, such as poor bioavailability, limit 
its effectiveness, semisynthetic derivatives of artemisinin have been developed. Among 
derivates, dihydroartemisinin (DHA) is the active metabolite of all artemisinin 
compounds (artemisinin, artesunate, artemether, etc.) and is available as drug itself.  It 
is a semi-synthetic derivate of artemisinin and is widely used as an intermediate in the 
preparation of other artemisinin-derived antimalaria drugs [31]. The proposed 
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mechanism of action of artemisinin involves cleavage of endoperoxide bridges by iron, 
producing free radicals (hypervalent iron-oxo species, epoxides, aldehydes, and 
dicarbonyl compounds), which damage biological macromolecules causing oxidative 
stress in the cells of the parasite [32]. Malaria is caused by apicomplexans, primarily 
Plasmodium falciparum, which largely reside in red blood cells and itself contains iron-
rich heme- groups (in the form of hemozoin) [33]. In 2015 artemisinin was shown to 
bind to a large number targets suggesting that it acts in a promiscuous manner. Recent 
studies discovered that artemisinin targets a broad spectrum of proteins in the human 
cancer cell proteome through heme-activated radical alkylation [34].  
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1.4.2 Artemisinin-based combination therapies (ACTs) and resistance 
to antimalarial drugs.  
 
Artemisinin-based combination therapy is a combination of a rapidly acting artemisinin 
derivative with a longer-acting partner drug. Artemisinin-based combination therapies 
(ACTs) are recommended by WHO as the first-and second-line treatment for 
uncomplicated P. falciparum malaria as well as for chloroquine-resistant P. vivax 
malaria. ACTs combine an artemisinin derivative with a partner drug. The role of the 
artemisinin compound is to reduce the number of parasites during the first three days of 
treatment (reduction of parasite biomass), while the role of the partner drug is to 
eliminate the remaining parasites (cure). The artemisinin component rapidly clears 
parasites from the blood (reducing parasite number by a factor of approximately 10.000 
in each 48-h asexual cycle) and is also active against the sexual stages of parasite that 
mediate onward transmission to mosquitos [23]. However, the efficacy of ACTs is 
threatened by the emergence of both artemisinin and partner drug resistance. Partial 
resistance to artemisinin causes delayed parasite clearance following treatment with an 
ACT. Such resistance does not usually lead to treatment failure; however, if the 
artemisinin component is less effective, the partner drug has to clear a greater parasite 
mass, jeopardizing the future efficacy of the partner drug.  
In addition, partner drug resistance can arise independently of artemisinin resistance. 
Given that an effective partner drug is essential for clearing all remaining parasites, 
partner drug resistance carries a high risk of treatment failure. Because of their different 
roles, the efficacy of the artemisinin and the partner drug must be monitored 
concomitantly but separately.  
WHO currently recommends five different ACTs. However, WHO is considering the 
use of artesunate-pyronaridine, a new ACT that has received a positive scientific 
opinion from the European Medicines Agency (EMA), in areas where other ACTs are 
failing. In the absence of resistance, all six partner drugs would be highly efficacious as 
monotherapies at the dose used in the ACT. Two injectable treatments, artesunate and 
artemether, are recommended for the treatment of severe malaria and should be 
followed by an ACT once the patient can tolerate oral therapy.  
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1.4.3 Antimalarial drug resistance 
 
Resistance and treatment failures to antimalarial medicines can be defined as follows: 
Antimalarial resistance is defined as the ability of a parasite strain to survive and/or 
multiply despite the administration and absorption of a drug given in doses equal to or 
higher than those usually recommended but within tolerance of the subject; 
Artemisinin partial resistance is defined as delayed parasite clearance following 
treatment with an artesunate monotherapy or with an ACT – this represents partial 
resistance; 
Multidrug resistance (MDR) is resistance to more than 2 antimalarial compounds of 
different chemical classes. This term usually refers to P. falciparum resistance to 
chloroquine, sulfadoxine-pyrimethamine, and a third antimalarial compound; 
Treatment failure is the inability to clear parasites from a patient’s blood or to prevent 
their recrudescence after the administration of an antimalarial. Many factors can 
contribute to treatment failure, including incorrect dosage, poor patient compliance, 
poor drug quality, and drug interactions and resistance. Most of these factors are 
addressed by therapeutic efficacy studies [35].  
In reporting the findings of therapeutic efficacy studies, the term "ACT resistance" is 
imprecise. ACT treatment failure (defined as treatment failure following treatment with 
an ACT, regardless of the presence of artemisinin partial resistance) is a more 
appropriate term that notes the specific ACT and the nature of the resistance if 
confirmed (i.e. artemisinin partial resistance or partner drug resistance, or both). The 
problem of antimalarial drug resistance is compounded by cross resistance, in which 
resistance to one drug confers resistance to other drugs that belong to the same chemical 
family or which have similar modes of action. 
Clinical artemisinin resistance is defined as delayed parasite clearance; it represents a 
partial/relative resistance that has thus far only affected ring-stage parasites. Delayed 
parasite clearance following treatment with an ACT is of paramount concern to WHO.  
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Possible future consequences of slow parasite clearance, or partial resistance, include: 
a) the development of total artemisinin resistance; b) the loss of artemisinin as an 
effective treatment for severe malaria; and c) increased de novo resistance to the partner 
drug, particularly in patients with high parasitaemia at admission, and/or greater 
selection of partner drug resistance. If resistance to partner drugs increases, treatment 
failures are likely to increase in parallel. Nevertheless, the majority of patients who have 
delayed parasite clearance following treatment with an ACT are still able to clear their 
infections, as long as the partner drug remains effective. 
The identification of the PfKelch13 (K13) mutations has allowed for a more refined 
definition of artemisinin resistance that includes information on the genotype. However, 
we have yet to fully understand which specific mutations within the K13 domain are 
most associated with artemisinin resistance. The current definition of artemisinin 
resistance is subject to change based on new evidence. 
The presence of artemisinin resistance is generally first evaluated during therapeutic 
efficacy studies (TESs) in which patients receive treatment with an ACT. It can also be 
evaluated in special clinical studies designed to evaluate artemisinin resistance; for such 
studies, patients receive artesunate monotherapy alone or before receiving a partner 
drug. The following definitions apply to both study types:  
Suspected endemic artemisinin resistance is defined as:  
 ≥ 10% of patients with a half-life of the parasite clearance slope ≥ 5 hours after 
treatment with ACT or artesunate monotherapy; or  
 ≥ 5% of patients carrying K13 resistance-confirmed mutations; or  
 ≥ 10% of patients with persistent parasitaemia by microscopy at 72 hours (± 2 hours; 
i.e., day 3).  
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Confirmed endemic artemisinin resistance is defined as:  
 ≥ 5% of patients carrying K13 resistance-confirmed mutations, all of whom have been 
found to have either persistent parasitaemia by microscopy on day 3 or a half-life of the 
parasite clearance slope ≥ 5 hours after treatment.  
Evaluations of artemisinin resistance has to take into consideration several confounding 
factors, such as the effect of partner drugs, host immunity, insufficient levels of drug in 
the blood, and non-validated K13 mutations. 
Artemisinin resistance alone rarely leads to treatment failure. However, resistance of 
malaria parasites to ACT partner drugs can lead to treatment failure (regardless the 
presence of artemisinin partial resistance). As a consequence, WHO in the 2018 Malaria 
report showed the maps of several ACTs that are failing (Artesunate-Amodiaquine) in 
Greater Mekong area (Fig. 10) 
The Greater Mekong Subregion (GMS) has long been the epicenter of antimalarial drug 
resistance, and currently P. falciparum resistance to artemisinin is present in five 
countries of the subregion: Cambodia, Lao People’s Democratic Republic, Myanmar, 
Thailand and Viet Nam.  
 
Fig. 10. Number of ACTs with high failure rates in the treatment of P. falciparum infections 
Source: Data were derived from the WHO global database on antimalarial drug efficacy and 
resistance 
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Taking in consideration the increasing resistance, monotherapy with artemisinin and 
ART derivatives is strongly not recommended and is substituted with ACT as standard 
therapy.  
 
1.4.4 Syk Inhibitors as a treatment for malaria  
 
The development and research of new antimalarial drugs is necessary to avoid 
increasing parasite resistance. A promising approach in the antimalarial therapy consists 
in utilization of Syk kinase inhibitors with the purpose to block the expulsion of 
denatured haemoglobin and its accumulation inside the parasitized erythrocytes [38] 
and not allow parasite growth, proliferation and egress from host cell.  
Notably, resistance is emerging in areas of low immunity given that P. falciparum 
transmission is declining in many areas including the Greater Mekong Subregion 
because of the scale-up of artemisinin resistance containment programs and malaria 
control programs to achieve national malaria elimination targets [36].  
As decreasing P. falciparum transmission will be accompanied by decreasing 
immunity, it will be important to understand the contribution of the immune system in 
the efficacy of the novel antimalarial drug.  
 
Spleen Tyrosine Kinase 
Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) 
which was discovered in 1990 and belongs to the Src family [37]. The Syk gene was 
found to be localized on chromosome 9q22 and is abundantly expressed in 
hematopoietic cells, such as mast cells, basophils, B-cells, T-cells, neutrophils, dendritic 
cells, macrophage, monocyte, erythrocytes, and platelets [38]. Syk is highly 
homologous to ZAP-70, which is present in the cytoplasm and is closely related to SYK 
in both homology and function. However, ZAP-70 expression is limited to T 
lymphocytes and natural killer (NK) cells. 
SYK and ZAP-70, possessing tandem N-terminal Src homology-2 domains (SH2) 
referred to as N-SH2 and C-SH2 domains. These are separated by interdomain A, and 
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the C-SH2 domain is followed by interdomain B which precedes the C-terminal kinase 
domain (fig 11).   
 
 
Fig. 11 Structural sequence of SYK kinase 
 
A tandem SH2 module (N-SH2 and C-SH2), has an important role in protein-protein 
interaction and serves as a docking platform for immune receptor tyrosine-based 
activating motifs (ITAMs) which are displayed on the cytosolic side of the plasma 
membrane. Importantly, the tandem SH2 domains also help to maintain SYK family 
kinases in an inactivated state via intramolecular interactions in resting immune cells. 
The interdomain linker SH2, between N-SH2 and C-SH2 constituted of 50 amino acids 
represents the most conserved region in family kinase. The interdomain linker of 80-
100 amino acids located between C-SH2 and catalytic domain is important to regulate 
the kinase activity and contains phosphotyrosine residues. 
The catalytic domain or SH1 constituted of 300 amino acids follows the interdomain 
linker. It contains the binding sites for ATP and two autophosphorylation sites (Tyr525 
and Tyr526). Finally, a C – terminal tail with unidentified function yet.  
The comparison of inactive and phosphorylated Syk structures reveals significant 
movement of the tandem SH2 domains region that could disrupt the interaction with the 
kinase domain characteristic of the inactive state. These data with that reported by 
different authors permitted the proposal of a model for the regulation of Syk kinase. 
Phosphorylation of erythrocyte membrane proteins has been previously documented 
following infection and intracellular growth of the malarial parasite, Plasmodium 
falciparum in red blood cells.  Much of this data dealt with phosphorylation of serine 
residues. Recently, instead, has been characterized of phosphorylation of serine and 
tyrosine residues of red cell membrane proteins following infection by P. falciparum 
[39]. Tyrosine phosphorylation of band 3 represented the earliest modification observed 
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during parasite development. Band 3 tyrosine phosphorylation observed at the ring 
stage appears to be under the control of Syk kinase. Identification of tyrosine 
phosphorylation of band 3, band 4.2, catalase and actin suggests new potential 
regulatory mechanisms that could modify the functions of the host cell membrane.  
 
Syk Inhibitor (R406) as a novel drug against Malaria. 
Band 3 serves not only to catalyze exchange of anion across the membrane but several 
function: to nucleate a complex of glycolytic enzymes on the membrane; provide a 
binding site for multiple kinases and phosphatases and anchor the spectrin-actin 
cytoskeleton to the bilayer [40]. All these functions contribute critically to the biology 
of red blood cells. In particular, its role in connecting the cytoskeleton to the membrane 
is extremely critical, in fact, the rupture of the band 3-ankyrin bridge or the band 3-
adducin bridge to the membrane skeleton based on spectrin leads to destabilization and 
fragmentation of the membrane [41].  
Band 3 has been shown to been important for the malaria parasites Plasmodium 
falciparum and Plasmodium vivax. As depicted in the figure 12, the parasite co-opts 
erythrocyte tyrosine kinase and activates the process of band 3 phosphorylation for its 
own benefit; the resultant destabilization of the membrane allows for egress of its 
merozoites and has been implicated in the ability of P.falciparum to form knobs and 
adhere to the microvasculature [42]. Recently, Pantaleo et al, showed a progressive 
increase in band 3 phosphorylation from ring to trophozoite to schizont stage. This is 
accompanied by an increase in band 3 containing microparticle formation their 
shedding and hemolysis. Band 3 phosphorylation is very plausibly due to oxidative 
stress exerted by the parasite growth because it is capable of activating the docking of 
Syk to band 3 and to inhibit Tyr phosphatases. Because this process eventually 
culminates in the rupture of the host cell membrane and release of the newly developed 
merozoites into circulation, Pantaleo and colleagues wondered whether selective 
inhibition of the tyrosine phosphorylation of band 3 might inhibit the phosphorylation-
induced membrane destabilization sufficiently to prevent parasite egress and thereby 
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terminate parasitemia. Indeed, Syk tyrosine kinase inhibitors were shown not only to 
prevent tyrosine phosphorylation of band 3 in P. falciparum pRBCs but also to decrease 
the subsequent release of membrane-derived MPs, to mitigate the loss of band 3 and 
Syk from infected cells, and to block the egress of mature merozoites from pRBCs. 
Syk inhibitors like R406 are under development at various stages and trials are currently 
underway investigating Syk inhibition in a wide range of disorders from chronic 
immune disorders such as immune thrombocytopenic purpura to malignancies such as 
retinoblastoma. Given their general safety in these initial trials, a case can be made for 
a clinical translational trial of a Syk TKI in malaria. 
 
 
 
Fig. 12. The biological activity of Syk inhibitors in infected erythrocytes. 
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Syk inhibitor and their molecular synthesis 
Imatinib: (4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridin-yl)-2-
pyrimidinyl]amino]-phenyl]benzamide (Fig.13 A). It is known as Gleevec in United 
States and Glivec in Europe, commercially available from Novartis. It is a drug non-
specific for Syk. Imatinib effectively suppressed parasitemia in culture, with essentially 
complete inhibition achieved at ~5 μM [41]. This Drug is already used for treating 
different cancer types, such as Chronic Myeloid Leukaemia (CML), Acute 
Lymphoblastic Leukaemia (ALL) and gastrointestinal stromal tumor (GIST). 
R406(tamatinib):6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-
2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-on (Fig.13 B). It is an active 
metabolite of prodrug R788 (fostamatinib) and a specific, ATP-competitive inhibitor of 
spleen tyrosine kinase (Syk), which plays a key role in signaling of Fc- and the B-cell 
receptor activation. R406 has an IC50 of 41 nM [43] and has already been used in 
clinical trials for rheumatoid arthritis [44] autoimmune thrombocytopenia [45], 
autoimmune haemolytic anaemia, IgA nephropathy [46] and lymphoma [47]. 
P505-15:4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-amino- 
cyclohexyl)amino)pyrimidine-5-carboxamide-hydrochloride (Fig.13 C). It is a novel, 
highly selective Syk inhibitor with an IC50 of 1 nM in cell-free assays. This  drug 
candidate has already been used in in vivo studies in mice for rheumatoid arthritis , non-
Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) treatment 
[48,49]. 
Syk-inhibitor-II: 2-(2-Aminoethylamino)-4-(3-trifluoromethylanilino)-pyrimi- dine-
5-carboxamide. It is a cell-permeable compound that acts as a potent, selective, 
reversible, and ATP-competitive inhibitor of Syk with IC50 41 nM (Fig.13 D) 
Syk-inhibitor-IV:2-(7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5- ylamino)-
nicotinamide (Fig.13 E). It is a cell permeable imidazopyrimidine compound that acts 
as potent ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine 
kinase activity (IC50 = 10 nM)  
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Fig. 13 Molecular structure of different Syk inhibitors such as Imatinib (A), R406 (B), P505-15 (C), Syk II (D) and 
Syk IV (E) 
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1.5 Malaria parasite clearance  
 
 
1.5.1 Spleen activity 
 
A key role in the control and clearance of intraerythrocytic infections is played by the 
spleen [50]. Its physiological function is to remove senescent red cells, malaria 
parasites, and circulating extracellular cells such as bacteria or cellular debris from the 
blood. As parasites grow and alter the surface of the host red blood cell, the spleen and 
its surveillance cells identify infected cells and prevent them from further circulation. 
The spleen consists of two overlapping blood circulations—a rapid flow by-pass, called 
the fast closed circulation, which typically takes 90% of the splenic blood flow (100–
300 mL/min in a healthy adult), and a slow-open circulation in which the blood is 
filtered through narrow inter-endothelial slits. This slow filtration allows the blood 
elements to be assessed for antibody coating and deformability. Abnormal cells which 
fail inspection and other particulate material are retained. In malaria, the spleen enlarges 
rapidly, and is often palpable (i.e. ≥3 times enlarged), and clearance function increases. 
Examined spleen of fatal human malaria showed marked accumulation of parasitized 
erythrocytes of all stages [50]. The “activated” spleen retains parasitized red cells 
(including ring stage infected cells) and it removes parasites and parasitized cells. 
Splenectomy and splenic dysfunction increase the risk of severe malaria [50]. Recent 
study in fact, has demonstrated that the splenic filtration of parasitized red blood cells 
is drastically reduced when the ability of splenic macrophages to phagocytose is 
blocked, with the consequence of rapidly achieving high total parasitemias in the body, 
comparable to that observed after splenectomy. Thus, macrophage dysfunction may 
explain the high burdens of asexual parasites in HIV-positive patients [51].  
The spleen also removes intraerythrocytic particles such as nuclear remnants (Howell-
Jolly bodies), denatured hemoglobin (Heinz bodies) or iron granules (in siderocytes) 
from intact erythrocytes without destroying the cells, a process so called, pitting. The 
“pitting” capability of the spleen is substantial. From 1960, Crosby and his research 
group showed that siderocytes could be pitted of their iron granules with a half-life of 
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80 min in healthy subjects suggesting that pitting rates were close to removal rates for 
abnormal erythrocytes. Through the same mechanism the spleen also removes damaged 
circulating intraerythrocytic malaria parasites without destroying the red cells [52]. This 
is the main mechanism of ring stage parasite clearance following treatment with 
artemisinin derivatives in non-immune patients [53]. As to the clinical aspect, it was 
noted that patients treated with artemisinins for P. falciparum malaria clear their 
parasitemias faster that those treated with quinine or other antimalarial drugs and that 
pitting contributes substantially to artemisinin-induced parasite clearance [53]. 
Furthermore, a recent study has been suggested that human immunity is the primary 
determinant of clearance rates, unless or until artemisinin killing has fallen to near-
ineffective levels [54].  
 
1.5.2 Antibody 
 
Human RBC show a very well-defined lifespan of 120 days. At the end of their life, 
RBC are removed from the circulation by splenic macrophages. In absence of the 
classical apoptotic pathway, RBC must possess a specific mechanism which triggers 
their recognition by macrophages at a defined stage of their life. A large number of 
modification were described in senescent RBC. They are smaller, denser, their surface 
is partially desialylated, haemoglobin is denatured and bind to the inner face of their 
membrane, and, finally, senescent RBC binds naturally occurring antibodies (NAbs).  
Band 3, the most represented RBC integral membrane protein, appears to be the major 
target of NAbs. Natural antibodies directed against modified band 3 (“senescent 
antigen”) bind to old erythrocytes resulting in their clearance from the circulation [55]. 
NAbs appears to bind only to modified band 3 (neoantigen), in particular, evidences 
indicate that band 3 clusters induced by hemichromes are always associated to intense 
NAbs binding [56]. Hemichrome binding to band 3 also causes the oxidative cross-
linking of their cytoplasmic domains. The band 3/hemichrome complex is found in 
many pathological conditions characterized by intense RBC splenic trapping 
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accompanied by anti-band 3 NAbs binding to RBC membrane, for example during 
intra-erythrocytic malaria parasites growth. 
Several authors have proposed mechanisms for recognition and phagocytic removal of 
senescent or damaged RBCs based on oxidative and non-oxidative clustering of band 3 
as the starting event with subsequent opsonization and phagocytic removal by 
circulating or resident phagocytes [55]. Marguerite Kay, was the first to show that dense 
human RBC bound increased amounts of autologous IgGs. After her data, band 3 
centered removal model has received great attention. According to Low’s model, 
aggregation of band 3 induces clustering of potential antibody-binding sites and 
promotes deposition of autologous IgGs. This mechanism does not imply covalent 
modifications of band 3 but simply assumes that antibodies with affinities too weak to 
bind to band 3 monovalently would react avidly with band 3 aggregates due to enhanced 
affinity of the bivalent interaction. Lutz et al, proposed another model, sharing element 
with Low’s model. Lutz demonstrate increased binding of anti-band 3 antibodies to 
band 3 oligomers in senescent RBC, a correlation between cross-linkability of band 3 
and anti-band 3 binding, and enhanced binding of anti-band 3 to aggregated band 3 on 
immunoblots. The fundamental difference respect to the Low model is the crucial role 
firstly described by Lutz of both anti-band 3 antibodies and complement deposition as 
mediators of opsonization and phagocytosis [55]. 
Membrane-bound anti–band 3 antibodies partially activate complement resulting in red-
cell membrane deposition of C3 fragments. The antibody-C3 complex is then readily 
recognized by phagocyte CR1 complement receptors [55]. This process may be 
accelerated in malaria infected red cells. The affinity for C3 may render these antibodies 
a preferential site of binding of the short-lived C3b and may result in a preferential C3b-
anti-band 3 complex formation. The role of immune haemolysis in the pathogenesis of 
malaria anaemia has been controversial. However, it is clear that the threshold for 
splenic recognition of erythrocyte bound antibody is lowered markedly in malaria, 
although there is substantial inter-individual variability. Thus, red cells with low 
antibody coating, which would normally escape clearance, are removed in malaria. As 
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with mechanical clearance, immune clearance usually increases after anti-malarial 
treatment has started.  
The effectiveness of innate immunity in malaria response has been documented. 
Response to band 3 neoantigens in subjects living in an area of intense malaria 
transmission is associated with lower parasitemia and improved haematological 
symptoms.  Infected RBC shows a stage dependent hemichrome binding to the 
membrane and a parallel opsonization by anti-band 3 antibodies and C3b. Hemichromes 
formation, band 3 clusterisation and its oxidation were proved to be essential factors to 
allow the opsonization by Nabs and complement. These events allow the involvement 
of autologous IgG with anti-band 3 specificity and complement, which are identified as 
the opsonins responsible for phagocytic recognition at ring-stage, the early parasite 
forms. At this stage, phagocytosis is modest and almost totally mediated by complement 
deposition and recognition by the phagocyte complement receptor type 1. Arese’s group 
research demonstrated also that at trophozoite stage and schizont stage, the 
phagocytosis was strongly increased and the role of complement in phagocytic 
recognition was reduced.   
Different research groups work on hypothetical mechanism to support the hypothesis 
that a common mechanism involving anti-band 3 Nabs appears to determine RBC 
removal in different physiological and pathological situations (Fig. 14). Oxidative 
denaturation of hemoglobin lead to hemichromes formation 1. Hemichromes, lead to 
band 3 clustering and to exposure of band 3 neo-antigens. Band 3 and several membrane 
proteins undergo phosphorylation in response to different stimuli. Band 3 cytoplasmatic 
domain, appears to be the substrate of RBC tyrosine kinases activated by oxidative 
stress.  The linkage between hemichromes and band 3 cytoplasmic domain cause their 
oxidative cross-linking through disulfide bonds and their Tyr phosphorylation 2. Band 
3 dissociation from cytoskeletal proteins and its clusterisation 3. Formation of large 
band 3/hemichromes clusters and opsonization by Nabs and C3b 4. These signal leads 
to recognition by immune cells.  
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Fig. 14. Proposed pathway involvement of anti-Band 3 Nabs. The band 3 – IgG/Complement RBC 
removal model. Sequence of events after oxidant damage of the RBC leading to opsonization with 
anti-band 3 IgG and complement, recognition and removal by the phagocyte. 1) After oxidant insult, 
denaturation of hemoglobin leads to hemicrome formation. 2) Hemicromes binding to band 3 
cytoplasmic domain cause their tyrosine phosphorylation. 3) Band 3 dissociation from cytoskeletal 
proteins and its clusterisation. 4) Formation of large band 3/hemicromes clusters and opsonization 
by Nabs and C3b. This signals leads to recognition by immune cells. 
 
1.5.3 Acquired immunity and parasite clearance 
 
Naturally acquired immunity to malaria develops after repeated exposure to parasites, 
is acquired faster in high- compared with low-transmission areas [36] and is lost after 
relative short time without exposure to the parasite.  P. falciparum antibodies are an 
important component of immunity and can target the sporozoite stage, reducing 
transmission and infection, and blood-stage parasites (merozoites, infected 
erythrocytes), reducing parasite multiplication and increasing parasite clearance rates, 
thereby suppressing parasite densities and clinical symptoms. Despite enormous 
research investment and effort immunity to malaria is still poorly understood. Immunity 
may confound the interpretation of parasite clearance measures in drug-efficacy studies. 
The main implications of an effect of host immunity on parasite clearance measures are 
that in populations with high levels of immunity and faster parasite clearance, early 
signs of multidrug resistance could be undetected, and conversely, in populations with 
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lower immunity and slower parasite clearance, a false impression of reduced drug 
efficacy could arise.  
 In general terms, the acute malaria infection is contained by non-specific host-defence 
mechanisms including splenic activation and fever (which inhibits schizogony). Later 
more specific humoral and cellular immunity control and finally eliminate the infection.  
In malaria-endemic areas, where people are infected frequently, most infections are 
controlled at densities causing little or no symptoms because after repeated malaria 
infections a person may develop a partially protective immunity (Fig.15) [57]. Such 
“semi-immune” persons have acquired clinical immunity and can still be infected by 
malaria parasites, which they tolerate without showing typical clinical symptoms of 
malaria . These persons can be considered as asymptomatic malaria parasite carriers 
The illness instead, results from infections to which the individual has insufficient 
immunity to control parasite multiplication. In areas of higher transmission illness most 
likely occurs in young children who have had few or no previous infections.  In older 
children and adults rapid mobilization of both non-specific and specific host-defense 
mechanisms usually results in prompt control of the infection—even without anti-
malarial treatment. As a result “immunity” complements the effects of anti-malarial 
drugs, accelerating parasite clearance and augmenting cure rates or, drugs could 
enhance immune recognition, thus favoring parasite clearance. Acquired immunity 
explains why cure rates are always higher in adults and older children in endemic areas 
and why anti-malarial treatment efficacy assessments in high transmission settings 
should always include young children. Infact, in areas with high P. falciparum 
transmission (most of Africa south of the Sahara), newborns will be protected during 
the first few months of life presumably by maternal antibodies transferred to them 
through the placenta. As these antibodies decrease with time, these young children 
become vulnerable to disease and death by malaria. In high transmission areas, young 
children are at major risk and are targeted preferentially by malaria control 
interventions.  It’s possible that variations in host immunity between- and within-
population influence parasite clearance after artemisinin treatment, confounding the 
current WHO working definitions of artemisinin resistance, and consequently the 
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interpretation of the geographical spread of artemisinin resistance. Several researchers 
question the role of the immune system that remains complex to understand. Uhlemann 
and Fidock [58], for example, sustained that the shift in parasite clearance rates with 
time could be caused by drop of immunity as interventions reduced exposure of patients 
to parasites and so the increasing failure rates of other drugs can be due to decreased 
immunity rather. Greenhouse and colleagues in their report [59] sustained that the 
increasing drug failure were due to decreasing levels of immunity rather than changes 
in parasites drug resistance levels. Thus, a consequence of an incomplete eradication of 
malaria by malaria control measures in a population results in a decrease of acquired 
immunity and increase of vulnerability for clinical malaria in the population. In this 
scenario a malaria drug that strengthens the innate immune responses is desirable. 
Surely, the optimal P.falciparum malaria drug would satisfy three demands, firstly to 
kill asexual parasite stages in the blood, secondly not to block but sustain the immune 
cell response to mount an efficient but not host-damaging immunity and thirdly, to 
attack gametocytes to inhibit transmission.  
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Fig. 15 Immune response with P. falciparum infection 
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1.6 Innate immune functions of the monocyte- 
macrophage  
 
1.6.1 Phagocytosis and oxidative burst 
 
Phagocytosis of parasitized RBC is triggered by IgG and Complement factors on the 
surface of RBC. Most studied IgGs are either autoantibodies against band 3 clusters, 
above defined as neo-antigens (innate immunity) or against parasite-specific antigens 
(acquired immunity). Specialized phagocytic cells express high levels of specific 
receptors for immunoglobulins (Ig), the Fc receptors CD 16, CD 32, CD 64, which 
recognize and bind the Fc portion of IgGs with different affinities, as single IgG or as 
immune cluster. Binding the Fc domain to its receptor activates phagocytic engulfment 
of IgG-labelled particles, e.g. an IgG-flagged pRBC, its intracellular transport and 
fusion with the lysosome and consequent degradation. Suitable antigen peptides are 
load up on MHC class II protein groove and transported for exocytosis and insertion 
into the membrane of the antigen-presenting cell. These last steps are crucial for linking 
innate immune response to acquired immunity and mounting the latter. Syk-dependent 
phosphorylation is crucially involved in the process of Fc-receptor signaling. In human, 
the molecular features of Fc receptors for IgG (FcγRs) have been extensively studied. 
FcγRIIA and FcγRIIC are known to possess intramolecular ITAM in the cytoplasmic 
region. Cross-linking of these receptors induces tyrosine phosphorylation of ITAM 
through Src-type kinases such as Hck, Lyn and Fgr, leading to the recruitment of Syk 
for activation. Activation of Syk is critical for production of cytokines and chemokines 
in response to cross-linking of FcγRs. In addition to FcγRs, Syk is critical for immune 
responses mediated by various antigen receptors such as the B-cell receptor (BCR) and 
high-affinity IgE receptor (FcεRI).  
Recently, the role of an adaptive protein, c-Abl Src omology (SH) 3 domain binding 
protein-2 (3BP2), has been studied. The 3BP2 protein was originally identified as an 
Abl-binding protein of unknown function but it was suggested that 3BP2 plays an 
important role in FcRγ-mediated phagocytosis Syk-dependent tyrosine phosphorylation 
of 3BP2 (P) is critical for optimal FcRγ-mediated phagocytosis. In fact, phosphorylation 
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of Tyr174, 183 and 448 by Syk kinase in 3BP2 is a requirement for 3BP2 to induce 
FcRγ-mediated phagocytosis [60]. 
Similar to IgG, complement factor 3b (C3b) is deposed on the pRBC membrane and 
elicits phagocytosis by monocytes and monocyte derived macrophages when 
recognized by complement receptor 1 (CR1).  
Both receptors Fc-gamma as well as CR1 are able to elicit oxidative burst, a mean of 
the monocyte and granulocyte to destroy the parasite in the circulation followed by the 
appearance of crisis forms that have to be removed in the spleen by pitting or 
phagocytosis.  The INF-gamma seems to play a key role due to FcR and CR expression. 
Recent studies have focused on the role of IFN-γ in regulating the phagocytic capacity 
of macrophages, as its role remains to be considered controversial. It has been reported 
that IFN-γ improves the phagocytic activity of macrophages, also leading to the up-
regulation of FcRI (or CD64, the high affinity Fc receptor for IgG) and CR expression 
with an increase in phagocytosis of opsonized pathogens. In fact, in vivo treatment of 
normal human subjects with IFN-γ led to increased expression of FcγRI by their 
phagocytes and a related improvement in FcγR-mediated phagocytosis by neutrophils.  
Futhermore, IFN-γ treatment is associated with increased expression on monocytes of 
the opsonic receptors FcγRII, FcγRIII and C3. However, it was also observed that IFN-
γ significantly inhibits non-opsonized phagocytosis of macrophages. "Activation" of 
macrophages induced by IFN-γ for opsonized particles and inhibition for non-opsonized 
particles, seems to be sought in the down-regulation in the expression of MARCO, the 
main surface-binding macrophage receptor for non-opsonized particles. Thus, INF-γ 
plays distinct roles in opsonized and nonopsonized phagocytosis [61].  
The secretion of IFN-γ by human and natural killer (NK) T cells induced by synergistic 
costimulation with interleukin (IL) -12 and IL-18 is well established [62]. The 
contribution of macrophages to the release of IFN-γ could be a significant factor in 
understanding mechanisms that induce phagocytosis but a similar activity in 
macrophages is still controversial. It has been shown that human macrophages derived 
from monocytes in vitro through stimulation with a combination of IL-12 and IL-18 or 
with macrophage colony-stimulating factor (M-CSF) were able to produce IFN-γ when 
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further stimulated with a combination of IL-12 and IL-18. The release of IFN-γ results 
in a high level of proinflammatory cytokines and a low level of anti-inflammatory 
cytokines to promote the immune response, promoting the phagocytic capacity of 
macrophages to eliminate the pathogen. 
Based on these considerations understanding the contribution of the immune system, 
especially innate immunity in the treatment of malaria is of fundamental importance in 
an age where great efforts are concentrated to identify new antimalarial drugs, which 
could, with the aid of immune system, promote parasite clearance.  
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1.7 Antimalarials and immunity 
 
Innate and adaptive immune functions   assaulting malaria parasites include a network 
of cytokines, ROS production and involve immune cells, comprising neutrophils, 
activated macrophages, natural killer (NK) cells, dendritic cells, and T-cells. Both cell-
mediated and humoral components of immune system serve their actions and activities 
to prevent malaria infection by promoting phagocytosis, elimination of infected red 
blood cells and subduing merozoite intrusion of erythrocytes through antibody-
mediated neutralization.  
To understand how drugs affect the immune system is very important in order to treat 
a disease successfully leading to improvement of clinical symptoms and reducing 
unwanted side effects. Drugs of all types and classes affect the immune system, but the 
mechanisms responsible for these effects are often misinterpreted [63]. Some drugs 
target immune cells specifically for the treatment of immunological diseases, such as 
B-cell lymphomas, while other drugs for the treatment of rheumatoid arthritis have 
immunosuppressive or anti-inflammatory effects [64].  Artemisinin and its derivates are 
currently considered the most effective drug in the treatment of cerebral malaria and 
chloroquine-resistant P.falciparum malaria. The peroxide group is essential for the 
medicines of the artemisinin family to exert antimalarial effects. In addition to their 
excellent clinical antimalarial effects, recent studies promoted the drugs of this family 
as potent anti-inflammatories and able to regulate innate and adaptive immunity.  
Macrophages, have a double-faced role in cell-mediated (act as antigen presenting and 
effector cells) as well as in humoral immunity (phagocytose opsonized microbes) and 
can produce both pro-inflammatory cytokines, such as IL-12/ and TNFα, and anti-
inflammatory cytokines, including IL-10. Several research group found that 
Artemisinin family drugs inhibit the secretion of macrophage-derived proinflammatory 
cytokines, particularly TNF. Results of recent study manifested that artemisinin can 
abolish NF-kB mediated release of TNF and IL-1beta proinflammatory cytokines in 
human adherent monocytes [65]. Artemisinin family drugs could also induce the anti-
inflammatory cytokine production, such as IL-10, whereas decrease IL-12 production 
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in primary peritoneal macrophages after IFN-γ stimulation in vitro or in vivo. These 
studies suggest that artemisinin family drugs are able to suppress the activation of 
macrophage. Looking from the perspective of early innate immunity against malaria, in 
which proinflammatory cytokines themselves and their capacity to mediate activation 
of phagocytic macrophages is of great importance, the prevailingly suppressant nature 
of artemisinins against cytokines release, macrophages viability, and phagocytic 
capacity might raise highly relevant and important questions about their apparent 
immunosuppressant capability. However, data from in vitro and in vivo studies on 
immune modulatory effects of Art are often inconsistent.  Initial studies with highly-
dosed Artesunate showed a significantly decreased phagocytosis of peritoneal 
macrophages and phagocytic index in vivo, reducing the weight of thymus in Artesunate 
treated mice. Treatment of Plasmodium berghei infected mice with Artesunate, 
enhanced the serum C3 level. Clinical trials showed that serum IgM and IgG levels were 
increased but serum C3 contents were reduced in malarial patients. These data led to 
attribute an inhibitory effect on the humoral immunity to Art and the regulating the C3, 
which was beneficial to form immune complexes in patients suffering from malaria or 
autoimmune and immune complex disease [66]. 
In vitro experiments with Art showed inhibited lymphocyte proliferation induced by T 
cells mitogens.  
T lymphocytes play a fundamental role in adaptive immune responses to guide cellular 
and humoral immunity. Following binding to the antigen, T cells are activated and 
secrete IL-2. Subsequently, through the autocrine / paracrine proliferative cycle, IL-2 
induces clonal expansion, promotes the survival of activated T cells; after the correct 
elimination of pathogens, activated T cells undergo apoptosis to maintain immune 
homeostasis [67]. Artemisinin family drugs can suppress T cell activation both in vitro 
and in vivo. Artemether was reported to suppress T cell proliferation and IL-2 
production in response to TCR engagement or mitogens in vitro.  
B lymphocytes are essential for mounting adaptive immunity and play a critical role in 
the humoral immune response by secreting antibodies. Artemisinin family drugs have 
been shown to preferentially affect antibody production upon antigen immunization 
anda significant inhibition of LPS-induced B cell proliferation has been demonstrated.  
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In contrast, studies conducted in children and adults with uncomplicated Malaria in 
endemic areas as Burkina Faso, have demonstrated that use of ACT based therapies 
have no influence on the antibodies response against experimental malaria antigens. 
The different dosages and different assays applied in in vivo mice and clinical studies 
may explain conflicting results. In mouse artemisinin derivatives were given daily for 
7 days while in children three doses were prescribed. It is very likely that drug treatment 
and antibodies are clearing parasites in synergy since elderly children resolve the 
infection in shorter time. 
Immune pharmacologic actions of artemisinin drug family deserve further investigation 
to understand also the enigmatic relationship between malarial parasite and host 
immunity that allows a sustained persistence of parasites in otherwise efficient immune 
system. Perception of several aspects of host immune responses to malarial parasites is 
essential, not only for novel drug development but also for understanding the 
interference of existing anti-malarial drugs with host's anti-malarial immunity. 
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2. AIM OF THE PROJECT 
 
Since 2001, the WHO has recommended ACTs for treatment of uncomplicated malaria 
caused by P. falciparum. ACTs have been an integral part of the recent success in global 
malaria control. However the WHO has observed foci of suspected artemisinin 
resistance in South-East Asia and emergence of resistance to both artemisinin and the 
partner drugs endangers the future ACT efficacy. Because strains of P falciparum are 
rapidly emerging that are resistant to all known antimalarial drugs, including 
artemisinin, quinine, chloroquine, piperaquine, and mefloquine and their derivatives, 
emphasis is currently laid on comprehension of new therapies with novel mechanisms 
of action that includes also the patient’s immune response. The primary objective of 
research efforts is to reduce the risk of recrudescence. A new pharmacological treatment 
for malaria should lead to a faster elimination of parasites from blood with consequent 
improvement of symptoms and clinical prognosis and to interrupt transmission. 
Recently, Pantaleo et al, has demonstrated that Syk Inhibitors could represent a new 
class of antimalarial drugs reducing parassitaemia by delay of P.falciparum growth and 
suppression of  merozoite egress. Anti-parasitic activity of Syk inhibitors was shown in 
in vitro cultures of P. falciparum laboratory strains and field isolates. A crucial point 
for the anti-parasitic activity of Syk inhibitors is the persistence of anchorage protein 
band 3 in the membrane of maturing blood stage parasites. On the other hand band 3 is 
well known as platform for autoantibody binding to RBCs, the widely accepted 
mechanism for recognition of senescent RBC, RBC in several hereditary anemias and 
PRBC by spleen phagocytes. 
 These facts led us to focus on the role of immune processes in the decrease of 
parasitemia of P. falciparum after treatment with Syk inhibitors. 
 
The main goal of my research was to test new effective antimalarial combinations that 
possess the capacity to potentiate artemisinin effect, and to investigate the mode of 
action of R406 hypothesizing an involvement of host immunity. 
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Specific aims of my studies were firstly, to verify the improvement of innate immune 
mechanisms, such as phagocytosis of young ring-stage PRBC; by artemisinin alone and 
in combination with a Syk-inhibitor 
Secondly to study the involved immune mechanisms that lead to an improved 
recognition by phagocytes of ring-stage PRBC if treated with Syk inhibitors and thirdly 
to demonstrate RBC membrane changes induced by Syk inhibitors, that cause increased 
binding of opsonins. Finally, first field studies will evaluate in malaria patients in 
Vietnam the efficiency of the innovative combination therapy with Syk-inhibitors.   
In order to achieve above objectives: 
- phagocytosis of ring-stage parasitized RBC (PRBC) by primary human 
monocytes was assessed after dose–dependent treatment of RBC with the active 
derivative of artemisinin DHA or Syk inhibitor R406 or the combination of both. 
-  levels of opsonins, IgG and complement factor C3c on ring-PRBC was assessed 
after treatment of RBC with DHA, R406, or both. 
-  Syk-inhibitor dependent accumulation and aggregation of band 3 proteins in the 
membrane of PRBC were tested. 
Parasite clearing was assessed in malaria patients treated with established ACTs vs. 
Syk-inhibitor/DHA combination. The results of this study may hopefully contribute to 
the establishment of an urgently needed innovative artemisinin-based combination 
therapy for malaria.   
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3. MATERIAL AND METHODS 
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3.1 Plasmodium falciparum (P.f.) in vitro cultures, 
separation, synchronization and ring stage-specific 
stage-enrichment procedures. 
 
3.1.1 Permanent P.f. cultures  
 
Human red blood cells parasitized with Plasmodium falciparum (Palo Alto strain, 
Mycoplasma free) were cultivated in growth medium (GM), consisting of RPMI 1640, 
HEPES modification from Sigma (Saint Louis – Missouri - USA), supplemented with 
20mM glucose, 2mM glutamine, 25 uM adenine, gentamicin 25 mg/ml, 1% (w/v) 
Albumax I. The cultures were permanently kept at 1% of hematocrit, in an air/ 
CO2atmosphere of 95%/5% vol/vol) at 37 °C. GM was changed daily and parasitemia 
maintained between 5-10 % by adding washed RBCs from healthy donors.  
Heparinized blood samples from healthy adult donors of both sexes were obtained from 
the local blood bank (A.S.L TO 4, Ivrea, Italy). Red blood cells (RBCs) were separated 
from plasma, platelets and white blood cells by three washes at 1800 rpm for 10 minutes 
in wash medium (RPMI 1640, HEPES modification), and stored at 4°C after 
resuspension in WM at 50% hematocrit and supplementation of 2% (v/v) saline-
adenine-glucose medium (SAG: 150 mM NaCl, 1.25 mM adenine, 45 mM glucose). 
 
3.1.2 Synchronization and infection of not-parasitized donor RBCs   
 
One day ahead experiments with ring-parasitized RBCs, preferentially late trophozoite 
and schizont stage P.f. cultures were loaded on the top of a 10, 40, 80 % (v/v) 
discontinuous Percoll gradient containing 6 % (w/v) mannitol and centrifuged for 30 
minutes at 3800 rpm and 30 C without brake. The mature parasites were collected from 
the 40/80 % interphase, washed once with RPMI 1640 and the re-infection of fresh 
washed RBCs from a healthy donor was performed by inoculating mature 
trophozoite/schizont stages into a RBC suspension in GM at hematocrit of </= 1 %. 
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Parasitemia was adjusted to 5-7.5 % and culture kept overnight at 37 °C in an air /CO2 
cell incubator.   
3.1.3 Enrichment and harvesting ring-stage parasitized RBC 
 
All experiments were conducted after opportune synchronization of cultures, carried 
out the same day of experiment with two aims: 1) elimination of not-Ring stage 
parasites and expelled hemozoin and 2) increase of ring-stage parasites by separation 
from not-parasitized RBC and to obtain ring stage parasites, useful for DHA and R406 
incubation experiments. For synchronization of cultures by parasite stage, schizont, 
trophozoite and ring stage parasites were collected after passing a synchronized culture 
at predominantly ring stages through a discontinuous Percoll ™ (GE Healthcare) 
density gradient. Precisely, solutions with different concentrations of Percoll (90, 80, 
40 and 10% (v/v)), each supplemented with 6 % mannitol (w/v), were stratified at 3, 2, 
2 and 1ml, respectively, into a 15 ml tube from bottom to top. Approx 1 ml cells of the 
P.f.  - cultures were loaded at a hematocrit between 15-30 % on top of one Percoll 
density gradient and centrifuged at 3800 rpm for 30 minutes (no brake). After 
centrifugation, different life cycle stages of parasite enrich in different fractions. 
Hemozoin enriches in the 10% to 40% interface, trophozoites/schizonts in the 40% to 
80% interface. Rings at nearly 100% parasitemia were collected from the 90 % percoll 
cushion above the bottom fraction and ring-parasitized RBC at lower parasitemia from 
the bottom fraction for stage-specific incubation with DHA and R406 (Schwarzer et al, 
Blood 2003). Collected parasites were washed twice in RPMI 1640, HEPES 
modification (Sigma) and incubated for metabolic recovery after separation in GM for 
1 hour at 37°C before incubation with DHA and R406. 
 
3.1.4 Handling of not-parasitized control RBC (npRBC)   
 
TRBC of the same donor that we used for reinfection were treated in parallel cultures 
including separation on percol. 
 
  60 
 
3.2 Phagocytosis assay 
 
3.2.1 Preparation of adherent human monocytes 
 
For phagocytosis experiments I isolated monocytes from buffy coats obtained from 
450ml blood donations which were provided by the local blood bank (A.S.L TO 4, 
Ivrea, Italy). One buffy coat from one blood donation of about 50 ml was transferred 
into two 50 ml tubes (Greiner) under sterile conditions and each one filled up to 50 ml 
with RPMI 1640 and resuspended.  
Resuspended buffy coat cells were deprived of platelets by centrifugation at 1000 rpm 
(no brake) for 20’ with subsequent removal of the platelet-enriched supernatant.  
Sedimented cells were resuspended with pre-warmed RPMI 1640 to obtain 120ml cell 
suspension. Thereafter, 30ml of suspension were carefully stratified on 15ml of Biocoll 
(Biochrom GMBH), isotonic cell separation solution with a density of 1.077g/ ml, 
avoiding mixing of the two solutions.   After centrifugation at 1700 rpm for 20’ without 
brake the fraction of peripheral blood mononuclear cells (PBMC), i.e. lympho- and 
monocytes, were found at the interphase between the transparent orange to red colored 
supernatant and the underlying transparent colorless Biocoll (fig.16). The supernatant 
consists of plasma diluted by cell culture medium. Erythrocytes and granulocytes pass 
Biocoll 1.077g / ml and sediment at the bottom.  
-  
 
Fig. 16 The separation of cells after centrifuge by Ficoll 
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The cells were sedimented by centrifugation at 1700 rpm for 7’and the supernatant was 
completely removed by careful aspiration to avoid the presence of Biocoll in the cell 
pellet.  The monocyte-enriched cell pellet was resuspended in 25 ml RPMI 1640. An 
aliquot of suspension was used for manual cell counting in a haemocytometer (Bürker 
chamber). 
PBMCs were suspended at 5 million cells/ml RPMI 1640 and plated in 24 well plates 
(Falcon) at 10 million per well [68]. A short adherence period was chosen to minimize 
lymphocyte adherence and after only 35 min incubation in a humidified incubator (5% 
CO2, 95% air, 37°C), non-adherent cells were removed by three washes with RPMI 
1640. Thereafter, adherent monocytes were re-incubated in 1 ml of M-SFM 
(Macrophage Serum Free Medium, GIBCO) / well for 5-10h until beginning 
phagocytosis experiments. The medium was changed immediately before adding red 
blood cells for the phagocytosis by monocytes.  
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3.2.2 Treatment of not-parasitized RBC (NPRBC) and parasitized RBC 
(PRBC) for phagocytosis  
 
All inhibitors were solubilized in anhydrous DMSO at 10 mM stock concentration and 
diluted in anhydrous DMSO prior to addition to malaria cultures avoiding excessive 
light exposure as indicated by the manufacturer 
Washed npRBC and PRBC resuspended in GM at hematocrit of 1%, and incubated for 
one hour for recovery after synchronization by Percoll centrifugation, were treated with 
different concentrations of inhibitors, i) Syk inhibitor R406 (Calbiochem), ii) 
dihydroartemisinin (DHA) (Selleckchem) or iii) both at variable concentrations and 
incubated at 37°C in an air/CO2 cell-incubator under routine cell culture conditions for 
indicated time. The handling of the substances and exposed cells was performed in the 
dark as explained above After incubation, RBCs were washed three time in 10 vol of 
Phosphate buffered saline – supplemented with 5mM Glucose (PBS-G). For all 
protocols described. Untreated controls were processed identically and run in parallel 
with the same final concentration of DMSO as the drug-treated cultures. 
 
3.2.3 Opsonization of NPRBC and PRBC  
 
Immediately before phagocytosis, washed Rh-positive NPRBC resuspended in PBS-G 
(50% hematocrit) were incubated with 25ug anti-D IgG/ml packed RBC for 30’ at 37°C 
as a positive phagocytosis control. NPRBC and PRBC treated with DHA, R406 or both 
were opsonized either with autologous fresh serum whenever possible or with human 
AB normal serum. For this, one volume of packed washed NPRBC or PRBC was 
supplemented with an equal volume of PBS and two volumes of serum, mixed and 
incubated for 30’ at 37°C. Thereafter, RBC were washed three times in 10 vol PBS-G 
and resuspended in PBS-G to obtain 10% hematocrit.  
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3.2.4 Phagocytosis of RBC  
 
About 10 million serum-opsonized or anti-D IgG-opsonized RBCs (10 ul of a 10% 
hematocrit suspension) were added (gentle mixing) to each well of a 24 well plate 
containing 10^6 monocytes at most. The plates were moved horizontally in all 
directions, making sure that the RBCs were well distributed in the well and equally 
cover the adherent cell layer. For a correct phagocytosis a ratio RBC to monocyte of 
approximately 100 should be respected [71]. After 3h of incubation at 37°C in 5% CO2/ 
95% air atmosphere, non-ingested RBC were removed from the wells by washing twice 
with PBS, followed by lysing not ingested but adherent RBCs by the addition of ice-
cold distilled water for 20 seconds and an additional washing step with PBS to remove 
extracellular hemoglobin. This treatment didn’t compromise the integrity of monocytes. 
Thereafter, adherent monocytes were solubilized by adding to each well 0,5 ml 
solubilizing solution (0,1 N NaOH, 0,025% Triton X-100, 3mM EDTA) for later heme 
quantification. Plates were stored overnight at 4°C. Phagocytosis was quantified by 
measuring ingested hemoglobin by a luminescence method using a Sirius Single Tube 
Luminometer (Titertek-Berthold) [72]. Heme-associated peroxidase activity catalyzed 
the electron transfer from tert-butylhydroperoxide to luminol (5-amino-2,3-dihydro-
1,4-phthalazinedione) at alkaline pH, which results in photon emission by reduced 
luminol. The amount of emitted light is proportional to the heme concentration in the 
tested sample [71]. In our assay, chemiluminescence was elicited by injecting 280 uL 
of a tert-butylhydroperoxid/EDTA solution (containing 3,7mM tert-butylhydroperoxide 
and 3mM EDTA dissolved in 0,1 N NaOH) as electron donor and in parallel 280 ul of 
0.1N NaOH/3mM EDTA supplemented with 19 mM luminol as electron acceptor into 
the test tube that contains an aliquot of the solubilized phagocytes. The injection of tert-
butylhydroperoxide triggered photon emission by luminol proportional to the amount 
of heme present in the sample and allows counting during 2 seconds. Photon counts per 
well were transformed into a number of RBC ingested by using a calibration curve 
constructed for each experiment with known amounts of cells of the same sample 
utilized for the phagocytosis experiment. Parallel to PRBC phagocytosis, opsonized 
NPRBC were added to monocytes in parallel and treated in the same way [73]. 
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The luminometer has two high precision reagent injectors set at 280 ul for each injector. 
The system simultaneously injects the two reactants that trigger the reaction (luminol 
and tert-butylhydroperoxide) providing the RLU values that will be used for heme 
quantification and statistical analysis.  
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3.3 Measurement of Oxidative burst 
 
The oxidative burst of monocytes is the enzymatic production of the superoxide radicals 
by NADPH oxidase which is assembled in membrane toward appropriate stimuli of 
receptors like Fc – complement or Toll-like receptors, but also after non-specific protein 
kinase C activation e.g. by phorbol ester.  
The oxidative burst of monocytes was quantified by measuring ROS-elicited luminol- 
based chemiluminescence by using Sirius Single Tube Luminometer (Titertek-
Berthold). The experiments were conducted using monocytes isolated from buffy coat, 
as described above. Human monocytes at 1,5 x 10^5 /ml M-SFM were incubated in 
suspension with different concentrations of R406 at 37°Cin a 95% air/ 5% C02- 
incubator). At indicated times 10^5 to 10^6 untreated control monocytes or treated 
monocytes were transferred into a luminometer cuvette containing 500 ul of PBS-G 
supplemented with 2mM Ca2+, 2mM Mg2+ and 10uM luminol [60]. Luminescence 
emitted by cells was monitored as RLU each 30 seconds until achievement of peak or 
plateau which indicates the basal ROS production of monocytes under study without 
further stimuli. At this time the total capacity of the cell to build up oxidative burst due 
to agonists was proven by adding phorbol 12-myristate 13-acetate PMA (100 nM). 
PMA elicits oxidative burst by a maximal and immediate activation of PKC 
independently of any receptor and RLU measurement each 30 seconds after PMA 
addition allows to determine the peak luminescence which is indicative for the maximal 
ROS production of cells at this time point considering the rather short luminol-based 
luminescence with a half-life of 8-9 seconds. This does not allow a real accumulation 
of luminescence signals (RLU) during the measuring time, as the precedent 
measurement adds just about 10% of its real value to the measurement after 30 seconds 
and nil after 60 seconds. All obtained data were collected for statistical analysis. 
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3.4 Immune precipitation  
 
Assuming R406 to favor binding of immunoglobulins to RBC [40], by band 3 
clustering, I decided to evaluate the amount of band 3 protein labelled with human 
immunoglobulins after treatment of cells with R406.  Immunoprecipitation (IP) is a 
procedure designed to precipitate a single antigen from a complex mixture using a 
specific antibody that recognizes the antigen and binds with its Fc portion to protein G 
attached to sepharose beads (fig.17). In my study I intended to precipitate and identify 
the membrane protein(s) of pRBCs that were recognized and bound by 
immunoglobulins of autologous serum.  For this extracted RBCs’ membrane proteins 
were incubated with the beads on which immunoglobulin –tagged proteins were bound 
by an IgG binding protein such as Protein G capturing the antibody-antigen complex. 
After binding antigen, the beads are washed extensively, and the antigen eluted from 
the support using an appropriate elution buffer.  
 
 
Fig. 17 Scheme of immunoprecipitation (IP) assay. 
 
More precisely, the method consists of the following steps:  
Firstly, synchronized ring stage pRBCs were incubated under previously described 
culture conditions in presence of 1 uM R406 at a hematocrit of 1%, and 37°C for 6 
hours. After incubation, NPRBC and PRBC were washed with PBS-G at 0°C. Secondly, 
washed RBCs were than resuspended in wash medium and fresh autologous serum at 
33% hematocrit and a final serum concentration of 33% (vol/vol) for opsonization at 
37°C for 30 minutes [68]. Thereafter, RBC were washed three times with PBS-G at 4°C 
and RBCs were subjected to membrane preparation. 
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3.4.1 Preparation of Red Blood Cells (RBC) membranes 
 
RBC and parasitized RBCs (PRBC) from control and R406 treated PRBCs were lysed 
in hypotonic buffer (KH2PO4 10mM; pH=8, supplemented with EDTA 1mM) under 
non- reducing conditions in presence of Complete© protease inhibitor cocktail). 
I prepared the RBC membranes strictly on ice with ice-cold solutions and centrifugation 
was performed at 4°C.  
RBC lysis was performed by adding lysis buffer at ten-fold volume excess to the cell-
suspension keeping it on ice and shaking several times for 5 minutes. Thereafter, the 
lysate was distributed in microtubes of 1.5 ml, centrifuged for 3 min at 12500g and 
supernatant was discarded. The membrane – containing pellet was washed at least 5 
times at 12500g for 1 minute at 4°C. Wash steps were considered enough when a) the 
ghosts did no longer change color and b) the supernatant did not show any trace of 
hemoglobin. After washes pellets were unified and resuspended. Aliquots (1ul in 
triplicate) were taken for protein quantification, 10 ul were solubilized with Laemmli 
sample buffer as a ghost protein reference for western blot analysis. The remaining 
membranes (200 ul) were used to extract proteins in 3 volumes of extraction buffer (50 
mM Tris HCl, pH 8 supplemented with 150mM NaCl, 1% NP40, 1% Triton X100) for 
20 min at 4°C under gentle mixing. Not extracted material was sedimented by 
centrifugation for 5min in a refrigerated Eppendorf microfuge at 15000 rpm and 4 °C 
with slow deceleration. Supernatant was collected in a new Eppendorf tube 1,5 ml, 
while pellet was discarded. Aliquots (1 ul in triplicate) were taken from supernatant for 
protein quantification and a second aliquot of 10 uL was solubilized with Laemmli 
sample buffer 5 times concentrated for Western blot analysis. The remaining part were 
incubated with protein G – Sepharose (30 ul for 500 ug of protein) (GE Healthcare – 
Protein G Sepharose ™ 4 fast flow) for 5 hours at 4°C (gentle mixing). Thereafter the 
beads were washed three times adding 500 ul of extraction buffer (see above) and 
centrifuging for 1’ at 15000 rpm (no brake) in a refrigerated Eppendorf microfuge, 
adding 500 ul of and once adding 500 ul of 50 mM Tris HCl, pH 8 supplemented with 
150mM NaCl without NP40 and Triton X100. Laemmli sample buffer (5-times 
concentrated) containing 2% (w/v) DTT was added to packed beads at 1:1 ratio 
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(vol/vol), that were heated a 95°C for 5’ and subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS PAGE) and Western blot analysis with mouse 
anti-band 3 and goat anti human IgG antibodies.  
 
3.4.2 Protein quantification 
 
RBC ghost proteins were quantified according the Bradford method. Bradford BioRad 
Dye Reagent Concentrate (BioRad, Hercules, California, United States), was added to 
the diluted aliquots of ghosts, as indicated by the manufacturer, vortexed, incubated for 
10 minutes at RT and placed in the cuvette for the measurement of absorbance at 595 
nm in a spectrophotometer (Ultrospec® 2000, Amersham Pharmacia Biotech Italia, 
Cologno Monzese (MI), Italy). The standard curve with Bovine Serum Albumin (BSA, 
BioRad 2mg/ml) was obtained by measuring solutions of 0.5, 1.0 and 2.0 mg/ml in 
triplicate, obtained by serial dilution of the original standard. The protein concentration 
of samples was calculated based on the standard curve. Results were expressed in ug/ul 
and inserted in database. 
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3.4.3 Electrophoretic separation of proteins and Western blot 
 
The levels of Band 3 protein and the levels of IgG bound on the antigens surface were 
measured by SDS PAGE after transfer to a nitrocellulose membrane (Thermo Scientific, 
Waltham, Massachusetts) by western blot.  
Before electrophoretic run the solubilized protein samples were supplemented with beta 
– mercapto–ethanol 5% (v/v) final to reduce sulfhydryl groups of cysteine residues, 
braking down sulfur bridges and with 0,01% Bromophenol Blue to monitor the progress 
of polyacrylamide gel electrophoresis. The samples were boiled for 5 minutes to 
complete the denaturation. In parallel to protein samples, molecular weight markers 
(Amersham Full-Range Rainbow 12-225 kDa ) were loaded in the wells of the stacking 
gel prepared for SDS-PAGE. 
Running gels were prepared at 8% of acrylamide by mixing H20, 30% (w/v) acrylamide: 
N’, N’-methylene-bis-acrylamide solution (37.5:1), 1.5 M Tris (pH 8,8, final buffer 
conc.), 10 % sodium dodecyl sulfate (SDS), 10% ammonium persulfate (APS; SIGMA, 
St Louis, Missouri), 0,04 % tetramethylenthylene-diamine (TEMED). After 
solidification of the running gel, stacking gel of x % acrylamide was prepared by mixing 
H2O, 30% (w/v) acrylamide: N’,N’-methylene-bis-acrylamide solution (37.5:1), , 
stacking buffer 1,5 M Tris (pH 6,8; final buffer concentration ), 10 % SDS, 10 % APS 
and 0,04% TEMED, layered on top of the running gel and a 10- well comb inserted 
before solidification.  
Proteins solubilized in Laemmli buffer were load at 5-20 ug/ well of the stacking gel.   
The presence of SDS (sodium dodecylsulfate) in the Laemmli loading buffer is an 
anionic detergent that denatures proteins and gives them an uniform negative charge 
density and therefore allows proteins to be separated exclusively on basis of their 
molecular weight and not their intrinsic charge. Glycerol has the task of increasing the 
density of the sample to facilitate loading it into the gel well. Bromophenol blue is the 
tracer of electrophoretic run. Solubilized proteins (5-20 ug) were separated by SDS – 
PAGE in a gel with a thickness of 1mm and an acrylameide concentration of 8% (w/v) 
using Tris-Glycine running buffer (Tris base 0.25mM, glycine 0.192 M, SDS 0.1%) 
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using a MiniProtean II cell vertical apparatus (Bio-Rad). Electrophoresis was performed 
at 50 V for 15 minutes and subsequently at 150 V until the bromophenol blue tracer 
reached the lower edge of the gel. 
After completed electrophoretic run, separated proteins were transferred from the gel to 
nitrocellulose membranes (previously activated in transfer buffer containing Trizma 
base, glycine, SDS, and methanol 15%) in a BioRad submarine transfer apparatus Mini-
Protean® system. Transfer condition were 70 V for at least 3 hours at 4°C. To visualize 
protein bands the membrane was incubated with Ponceau Red solution (0.2 % (w/v) 
Ponceau Red in 6% (w/v) trichloroacetic acid) Ponceau Red binds NH3 groups of lysine 
and arginine and colors the transferred proteins red, while the gel was incubated with 
Coomassie Blue (Coomassie Blu R 0,2% (w/v), methanol 50% (v/v), acetic acid 7% 
(%), H20) to check whether the transfer was efficient. 
 
3.4.4 Assessment of proteins by immunochemistry after Western 
Blotting and Analysis of data 
 
Membranes were blocked with Bovine Serum Albumin (BSA 5% in PBS – Tween 0,1 
%) for 60 min to prevent antibody binding to the membrane and then incubated with 
primary monoclonal antibodies i) mouse anti-Band 3 protein antibody (Sigma, 1:25000 
diluted in 1% (w/v) BSA in PBS, supplemented with 0.1 %(w/v) tween) and ii) goat 
anti-human IgG (Sigma 1:20.000 diluted in 1% (w/v)  BSA in PBS, supplemented with 
Tween 0,1 % (w/v) (PBS-Tween) for 2 hours at 4°C. Thereafter, membranes were 
washed and incubated for 1 hour at RT with a secondary goat anti-mouse horseradish 
peroxidase (HRP) – conjugated antibody, diluted 1:40.000 (Santa Cruz Biotechnology) 
in PBS-Tween, supplemented with 1% (w/v) BSA for Band 3 evaluation, while with a 
secondary mouse anti goat horseradish peroxidase (HRP) – conjugated antibody, 
diluted 1:20.000 (Santa Cruz Biotechnology) in PBS-Tween, supplemented with 1% 
(w/v) BSA. 
protein bands recognized by antibody were detected using Enhanced 
Chemiluminescence (ECL) based on electron transfer from Hydrogen Peroxide to 
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luminol in presence of HRP, which is conjugated to the secondary antibody. Hence, 
visualizes band 3 protein and IgG bound to the aggregated surface antigens by 
luminescence. To collect and elaborate quantitative data of protein conjugates the 
luminescence intensity was acquired and transformed in optical density OD) by in a 
Chemidoc apparatus (Chemidoc™ Touch Imaging System, BioRad, Hercules, 
California) and densitometry analysis was performed by ImageLab™ (Biorad).  
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3.5 Flow Cytometry Analysis, Fluorescence-activated 
cell sorting (FACS) 
 
To understand the molecular causes of enhanced phagocytosis of PRBC after treatment 
with R406, DHA and their combination, I analyzed the level of IgG and C3c 
complement factor bound to the cell surface by flow cytometry. 
Synchronized ring stage PRBC were incubated under previously described culture 
conditions with different concentration of DHA and R406 at hematrocrit of 1% for 6 
hours at 37°C. Each reaction was terminated by three washes with PBS-glucose 
distributing PRBC in microtubes of 1,5 mL and any centrifugation step was performed 
at 4°C. Thereafter, PRBCs were adjusted to a hematrocrit of 50%, resuspended and 
opsonized with fresh autologous serum (ratio 1:1) for 30 minutes at 37°C. Opsonized 
PRBC were than washed three times with PBS-G.  
Preparation of Sample 
For each test sample 2uL of packed PRBC were sedimented by centrifugation at 15.000 
rpm for 1 min and re-suspended in 80 ul PBS-G, supplemented with 2% (v/v) fetal calf 
serum (FCS) and distributed in four Eppendorf tubes to obtain   0.5 ul of packed PRBC 
suspended in 20 ul.  
PRBC aliquots were incubated with the antibody as follows: 
Goat anti-human IgG F(ab’)2 FITC conjugated (Thermofisher) at a final diluition of 
1:50  
Goat Anti-human C3c FITC conjugated (Dako) final dilution 1:200 
Goat anti-human Ker FITC conjugated (Abcam) final diluition 1:200 (isotype control 
of 1.) 
Goat anti-rabbit IgG (whole molecule) FITC conjugated (Sigma) at a final dilution of 
1:100.  
In parallel other tubes with 1 ul of packed NPRBCs from the same donor were similarly 
treated to use it as negative control. Incubation was conducted for 30’ at RT in the dark.  
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Thereafter, PRBCs and NPRBCs were washed once, and resuspended in 400ul of PBS-
G FCS 2%. After washing the fluorescence of PRBCs was measured by FACS in an 
Easy Cyte Guava cytofluorimeter (Millipore, Burlington, Massachusetts).  
Statistical analysis 
To understand the effect of major antimalarial drugs as DHA and R406 (as a new 
candidate to cause an antimalarial effect) I try to evaluate the level of bound IgG and 
C3c complement factor on the surface of red blood cells. The obtained fluorescence 
data were analysed with InCyte Guava Software and presented as mean fluorescence 
intensity (MFI) [69, 70]  
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4. RESULTS  
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4.1 Chapter synopsis 
 
The result chapter consists of four main sections. Firstly, the effect of Syk inhibitor 
R406 on phagocytic activity of human adherent monocytes is described. In this section 
data are presented from experiments with three different concentrations of Syk inhibitor 
to evaluate their effect on phagocytic activity of the monocyte. Secondly, I show the 
assessment of oxidative burst of monocytes after their incubation with R406. Thirdly, 
the effect of Syk inhibitor on parasitized red blood cells respective their phagocytosis 
by the monocyte is presented. In this section, three different concentration of R406 (0.1 
uM, 0.5 uM, 1 uM) and their combinatory effect with different concentrations of the 
bioactive artemisinin derivate dihydroartemisinin (DHA) are evaluated. In the last and 
fourth section the modification elicited by R406 and DHA on the red blood cell 
membrane is presented as evaluated by measuring bound opsonins by flow cytometry. 
Furthermore, I present data obtained by immunoprecipitation experiments on 
clusterization of band 3 protein in the RBC membrane after R406 treatment obtained.  
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4.2 Impairment of phagocytic activity of monocyte 
after treatment with R406 
 
In order to reach our objectives, I tried as first approach to functionally characterize 
monocytes, involved in the PRBC phagocytosis, identifying the factors that may favor 
or inhibit their activity and studying their action in the presence of antimalarial drugs. 
The effect of Syk inhibitor R406 on phagocytic activity of human primary monocytes 
was studied after their incubation for 5 hours (37°C, 95% atmosphere, 5% CO2) at 
increasing concentrations (0; 0.05; 0.5; 1; 2.5 uM) with adherent phagocytes. 
Phagocytosis was measured after feeding monocyte with anti-D IgG treated Rh-positive 
RBCs by quantifying ingested hemoglobin.  
 
 
Figure 18: Impairment of RBC phagocytosis by human adherent monocytes after their pretreatment with 
Syk Inhibitor (R406). A) The figure represents the level of phagocytosis of human adherent monocytes, fed with 
anti-D IgG treated RBCs, after a previous treatment of monocyte with indicated concentrations of R406 for 5 
hours (37°C, 95% atmosphere, 5% CO2). Approximately 0.1-1 x 10^6 monocytes were fed with 10^8 RBC. After 
3h of phagocytosis non-ingested RBC were removed by washings and osmotic lysis. Ingested RBC were 
quantified as described in Materials and Methods. Luminescence data were transformed in number of RBC 
phagocytosed in each well.  
 
As shown in Figure 18, monocytes without pretreatment were highly responsive and 
phagocytosed anti-D IgG treated RBCs avidly while a significant and increasing 
impairment of phagocytic activity was observed after pretreatment of monocytes with 
R406 from 0.5 to 2.5 uM.  
0
5000
10000
15000
20000
25000
30000
35000
R 0uM R 0.05 uM R0.5 uM R1 uM R 2.5 uM
P
H
A
G
O
C
Y
TO
SI
S 
(R
B
C
s/
w
e
ll)
R406 concentrations (uM)
  77 
 
To evaluate whether priming of monocytes modulates the inhibitory effect exerted by 
Syk-inhibitor R406 on monocyte phagocytosis, cells were pre-treated for 16 hours with 
IFN-γ (Thermofisher Scientific, Waltham, Massachussets) at 30 ng/ml (50 U/ml) under 
standard cell culture conditions.  
Despite the incubation of human adherent monocytes with INF-ɣ, a decrease in the 
phagocytic activity of monocytes is observed with increasing R406 concentrations 
(Fig.19). However, higher concentrations of R406 are necessary to exert the same 
inhibition observed in unprimed cells and a significant inhibition is seen only at 1uM 
and higher in IFN-gamma primed monocytes (Fig.19). Even at the highest 
concentration tested, 2.5 uM, the phagocytosis rate is still 3-5 times higher compared to 
unprimed cells, i.e. approximately 10 % of control phagocytosis in IFN-gamma treated 
cells vs. 2.5% of respective control phagocytosis in naïve phagocytes.  
 
 
Figure 19: Impairment of Phagocytic activity of human adherent monocytes after their pretreatment with 
Syk Inhibitor (R406) in INF-ɣ-primed monocytes.  The figure represents the level of phagocytosis of human 
adherent monocytes, fed with anti-D IgG treated RBCs, after previous treatment of monocyte with INF-ɣ 
(30ng/ml) for 16 hours and subsequently with R406 at indicated concentrations for 5 hours at 37°C, in a 95:5% 
air: CO2 atmosphere).  
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4.3 ROS release (oxidative burst) by human monocyte 
after treatment with Syk inhibitor (R406) 
 
In order to verify modifications in the first line cellular response of human monocytes 
by R406, I analyzed the basal and phorbol-ester-elicited ROS release from cultured 
monocytes after treatment with R406 at different times of incubation by measuring 
luminol dependent chemiluminescence. Addition of R406 (0,5 uM – 1 uM) to adherent 
monocytes induced a decrease of ROS release (equivalent to oxidative burst). The 
capacity of monocyte to generate oxidative burst after PMA stimulation declined 
sharply after their treatment with R406.  
As shown in figure 20A, ROS release by untreated human monocytes increase 
immediately after adding PMA (3 minutes after starts the experiment) and reach a peak 
value 15 minutes after PMA stimulation. ROS released from human monocytes 
pretreated with 0.5 uM R406 mount slower, reaching peak production later and remains 
at lower levels than untreated control monocytes. Human monocytes pretreated with 
1uM R406 show ROS release values significantly lower than both control and 0.5 uM 
pretreated cells. R406 at concentration of 1uM reduce the ability of monocytes to 
respond to PMA, reaching less then 40% of control values only after 20 minutes of 
measurement. ROS release levels was reduced by 48% and 65% after 60 minutes 
incubation with 0.5 uM and 1uM, respectively.  
Figure 20B shows the dependency of PMA-elicited ROS release from human 
monocytes on the exposure time of cells to 0.5 uM - 1 uM R406. Incubation periods of 
30, 60 and 120 minutes with 0-1 uM R406 were studied. and oxidative burst declined 
progressively with an increase of incubation time with R406.  
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A) 
 
 
B) 
 
Figure 20: Inhibition of PMA-elicited oxidative burst activity in monocytes pretreated with R406. A) basal 
and PMA-elicited ROS release (oxidative burst) from monocytes after treatment for 60 minutes with different 
concentration of R406. B) Time course of PMA-elicited OS release from monocytes treated with R406. 
Immediately after isolation of PBMC from healthy donors, monocytes were kept as control, while aliquots were 
incubated with R406 (0,5 uM – 1 uM) at 37°C. Aliquots of 3,5 x 10^5 monocytes were taken at indicated times 
and ROS quantified by luminol enhanced luminescence. After measuring the basal luminescence in the presence 
of 10uM luminol, oxidative burst was elicited by addition of 100 nM PMA at 3 min. Panel represent results of 
one typical out of two separate experiments.  
 
 
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
0
.0
s
3
0
.0
s
1
m
2
m
 3
0
.0
s
3
m
4
m
5
m
6
m
7
m
8
m
9
m
1
0
m
1
1
m
1
2
m
1
3
m
1
4
m
1
5
m
1
6
m
1
7
m
 3
0
.0
s
1
9
m
2
0
m
2
0
m
 3
0
.0
s
2
1
m
 3
0
.0
s
2
2
m
2
3
m
2
4
m
R
O
S 
re
le
as
e
 (
R
LU
/s
)
Time (min)
CTRL R 0,5 uM R 1 uM
  80 
 
4.4 The levels of in vitro phagocytosis of PRBC before 
and after treatment with R406 and DHA 
 
The first line of defense against the intrerythrocytic parasite is provided by phagocytic 
cells, which recognize PRBC as non-self cells and attack them by the same response 
adopted against invaders. Progressively, from ring-stage on, parasite-harboring RBC 
are transformed into non-self cells, opsonized and phagocytosed by circulating and 
resident phagocytes. Opsonization of parasitized RBC occurs in nonimmune autologous 
serum. Several investigators explain phagocytosis of senescent and oxidatively 
damaged RBC and under malaria conditions by following removal model. Modification 
of band 3 and deposition of anti-band 3 antibodies are the first in a series of events, 
eventually leading to activation of alternative complement pathway and C3b deposition 
on the RBC membrane. The growing P. falciparum exerts oxidative challenge and 
induces profound modification in the host RBC membrane. In fact, band 3 
conformational changes were described in malaria PRBC, and band 3 clustering was 
further demonstrated to be determinant for the exposure of band 3 neo-antigens in the 
host RBC membrane.  
Thus, PRBC are recognized as non-self cells and phagocytosed. Deposition of 
immunoglobulin G (IgG) and complement on band 3 protein produce recognition 
signals for phagocytosis.  
In this section I evaluate the capacity of human monocytes to recognize and remove 
PRBC efficiently as principal line of defense in non-immune individuals and show 
changes in efficacy of phagocytosis after treatment of pRBC with R406 and DHA. The 
hypothesis is that R406 and DHA, alone and in combination, lead to increased binding 
of IgG and C3b complement factor on the RBC membrane, promoting the clearance of 
the parasite and suggesting an immune-modulating role of R406 as potential 
antimalarial drug. 
 Firstly, I tested the phagocytic activity of monocyte with PRBC at different life cycle 
stages including malaria pigment hemozoin (HZ). Non synchronous cultures of PRBC 
were fractionated to obtain non parasitized RBC (NRBC), ring stage parasite (RPRBC), 
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trophozoite stage parasite (TRPBC) and malaria pigment hemozoin. Serum-opsonized 
PRBC were phagocytosed more intensely than NPRBC and the level of phagocytosis 
depended on the parasite maturation stage. As shown in figure 21 phagocytosis 
increases with parasite maturation and is maximal with trophozoite stage parasite. As 
expected, malaria pigment hemozoin was most phagocytosed by human adherent 
monocytes. In this experiment I used human monocytes fed with malaria pigment as a 
positive control of phagocytosis and the stage-dependent phagocytosis was expressed 
as a percentage of control.  
 
 
 
Figure 21: Phagocytosis of noninfected and malaria-infected RBC as function of parasite development. 
Noninfected and infected RBC were fractionated from synchronous cultures by Percoll density gradient. After 
washing, RBC were opsonized with fresh non-immune serum and subjected to phagocytosis assay. (Parasitemia 
of 100% for rings and trophozoite stage). For details, see Materials and Methods. Monocytes fed with HZ were 
used as a positive control of phagocytosis and the levels of stage-dependend phagocytosis were expressed as 
percentage of positive control.  
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To evaluate the effect of antimalaria drug on phagocytosis of PRBC, I pretreated PRBC 
with different concentration of DHA (Figure 23A) and R406 (figure 23B). PRBC were 
fractionated from synchronous cultures by Percoll density separation. The phagocytosis 
experiments were conducted using the fraction of Ring stage collected from the 90 % 
percoll cushion above the bottom fraction and ring-parasitized RBC at lower 
parasitemia from the bottom fraction and incubated with DHA and R406. Figure 23A 
shows increasing phagocytosis levels by increasing DHA concentrations until 120% of 
control at 1uM DHA. While figure 23B shows an increasing phagocytosis level until 
0.5 uM R406 (117% of control) while there isn’t significant differences on phagocytosis 
levels with R406 1 uM. Observing smear of PRBC R406 treated, immediately before 
phagocytosis experiments we observed a delay of growth of parasite compared to 
control. The delay of growth of the parasite with the reduction of the parasitemia after 
treatment with R406 0,5 uM, helped us to consider R406 0.5 uM the optimal 
concentration for studies on the synergistic effect of a combination between R406 and 
DHA. Morphology of human adherent monocytes before and after fed with anti D – 
IgG opsonized RBC has shown in figure 22.  
 
 
Figure 22: Erytrophagocytosis by human adherent monocytes. Human adherent monocytes were isolated 
from buffycoat of healthy donor in a multiwell plate. Gimsa-stained of human adherent monocytes as control 
(panel left) and monocytes after incubation for 3 hours with anti D – IgG opsonized RBC (panel right).  
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    A) 
 
 
              B) 
 
Figure 23: Effect of DHA and R406 on phagocytosis of PRBC. PRBC were fractionated from asynchronous 
cultures by Percoll methods. After 5 hours of incubation with DHA (panel A) and R406 (panel B), PRBC were 
opsonized with fresh serum and subjected to phagocytosis assay. After 3 hours of phagocytosis, monocytes were 
lysed and phagocytosis was measured by the assay of heme-derived luminescence. For details, see Materials and 
Methods. The phagocytosis levels for DHA/R406-treated RBC of each donor were normalized by setting the 
phagocytosis value for untreated RBC of the same donor one. The not-normalized phagocytosis value for not-
treated RBCs was 30.000 fmol/well hemin +/- SE.  Normalized phagocytosis values are plotted.  Mean values 
±SD (N=20) 
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4.5 Synergistic effect of DHA and R406 on phagocytosis 
of RING-parasitized RBCs by adherent primary 
human monocytes. 
 
In order to analyze the in vitro complementary activity of Syk inhibitors (R406) on 
artemisinin efficacy, P. falciparum cultures were treated with different concentrations 
of DHA and R406 as described above (materials and methods).  
Figure 24 shows the synergic interaction between DHA 0,1 uM and R406 0.5uM after 
5 hour of incubation determining an increase of phagocytosis level. This result indicates 
very different mechanism of action and effects on plasmodium of Syk inhibitors as 
single agents, and in combination with DHA: a) at 0.5 uM concentration, R406 show 
measurable effect on phagocytosis of the parasite and when used in combination with 
DHA they potentiate the artemisinin activation and leads an a significant increase of 
phagocytosis level; b) higher concentration of R406 (1uM), in reverse, leads a 
impairment of phagocytosis level, presumably due to monocyte toxicity or red blood 
cell death. 
 
 
Figure 24: Sinergistic effect of DHA and R406 combination on phagocytosis of PRBC. PRBC were 
fractionated from asynchronous cultures by Percoll methods. After 5 hours of incubation of DHA and R406 PRBC 
were opsonized with fresh serum and subjected to phagocytosis assay. After 3 hours of phagocytosis, monocytes 
were lysed and phagocytosis was measured by the assay of heme-derived luminescence. For details, see Materials 
and Methods. The phagocytosis levels of PRBC- DHA/R406 treated were expressed as arbitrary units after set the 
PRBC untreated as value of one. Mean values ±SD (N=8) 
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4.6 Analysis by FACS of bound IgG and C3 on RBC 
antigens surface before and after treatment with 
Syk inhibitor 
 
In order to understand the molecular cause of enhanced phagocytosis, I have 
characterized the surface of RBC, PRBC, and PRBC treated with DHA and R406 
measuring the membrane bound IgG and C3c complement factor. 
The capture of microorganisms are modified cells is a necessary prerequisite for their 
killing and intracellular degradation. IgG class antibodies cover microorganisms or flag 
modified autologous cells such as the parasitized RBC, favoring phagocytosis by 
binding FcR receptors on phagocytic cells. The phagocytic cells express on their surface 
a series of receptors that, by directly binding the microorganisms, favor their capture 
even in the absence of antibodies. The expression of specific receptors for the Fc portion 
of the IgG however, that cover the microorganisms (fig.25). represents the main effector 
mechanisms of innate immunity. The efficiency of this process is significantly enhanced 
if the phagocyte binds the microorganism with greater affinity. 
 
 
Figure 25: Opsonization and phagocytosis mediated by antibodies. a) Opsonization by IgG; b) Binding to 
receptors FcɣR on the surface of monocyte; c) activation of monocyte by FcɣR transduction; d) phagocytosis of 
microorganism; e) killing of phagocytosed microorganism.   
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Another way to recognize, no-self cells can be mediated by a product of the activation 
of the complement system. The complement system therefore includes proteins that 
collaborate with each other in order to opsonize microbes, promote phagocyte 
recruitment and, in some cases, directly kill the microbe. The recognition of non-self 
cells by one of the three pathways of complement activation leads to the recruitment 
and assembly of additional complement proteins to form complexes with protease 
activity. The biological effects of the complement system are due to the binding of its 
components and its fragments generated during activation with the receptors expressed 
on the membrane of various cell types. The best characterized receptor is the CR1 
receptor which has the function of promoting phagocytosis also on monocytes.  
In this section of results, the aim of the experiments was to evaluate the mechanism by 
which DHA and R406 can lead to an increase of phagocytosis and to identify the role 
played by IgG and complement system activation, respectively, on enhanced 
phagocytosis.  
In order to reach our objectives, P.falciparum cultures, treated with R406, DHA and 
their combination, were opsonized with fresh human serum and, membrane deposition 
of C3c complement fragments and autologous IgG, two strong opsonins that play a 
fundamental role in inducing phagocytosis, was evaluated by flow cytometry. Analysis 
by flow cytometer allows to rapidly and reproducibly analyze a high number of cells, 
through the analysis of physical parameters and fluorescence. The principle of this essay 
is simple: the flow cytometer analysis of a parasitized erythrocyte population previously 
incubated with a fluorescent antibody provides a fluorescence value (see Material and 
methods). The fluorescence value of untreated parasitized red blood will be compared 
to the fluorescence of parasitized red blood cells treated with DHA and R406. 
In figure 26, I show the effect of different concentrations of DHA and R406 on 
membrane bound IgG. The results show that the level of membrane-bound IgG were 
increased after treatment with 0.1 uM DHA while decreased with higher concentrations 
(1 uM). Membrane bound autologous IgG increased by 26 and 18 % for 0.1 uM and 0.5 
uM DHA, respectively. Furthermore, IgG binding increased with increasing R406 
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concentration. A significant increase of membrane bound IgG by 26 % was observed 
after incubation 0.5 uM R406.  
Figure 27 shows the effect of different concentrations of DHA and R406 on membrane 
bound C3c. Similar to IgG, DHA augments also the C3c binding to the membrane. C3c 
increases with increasing concentration of DHA until 0,5 uM.  
Membrane bound C3c was significantly increased by 17 and 35% after RBC treatment 
with 0,5 and 1 uM DHA, respectively, while 0.5uM R406 provoked an increase of 29%. 
Not significant increase was detectable at lower concentrations of R406 (see 0.1 uM).  
Neither DHA nor R406 had effects on IgG or C3c binding to the membrane of NPRBC 
at any concentration tested.  
The observed increase of both C3c and IgG deposition on PRBC provoked by DHA and 
R406 suggests a role for opsonin-dependent PRBC phagocytosis in the antimalarial 
action of DHA and R406.   
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A) 
  
B) 
     
C) 
 
 
Figure 26: Effect of DHA and R406 on membrane bound autologous IgG. The level of membrane bound IgG 
after 5 hours of incubation with DHA (panel A) and R406 (panel B) was measured in PRBC after opsonization 
with fresh serum by FACS analysis. Histogramm (panel C) shows a fluorescence curve for PRBC treated with 
DHA (left) and R406 (right) One representative experiment out of eight with similar results. For details, see 
Materials and Methods. The level of membrane bound IgG of PRBC- DHA/R406 treated were expressed as 
relative mean fluorescence intensity (MFI) after setting the MFI value for each untreated PRBC sample one. Mean 
values ±SD (N=8) (* = P<0,005; ** = P<0,05) 
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A) 
 
 
B) 
 
 
 
Figure 27: Effect of DHA and R406 on membrane bound autologous C3c. The level of membrane bound C3c 
after 5 hours of incubation with DHA (panel A) and R406 (panel B) was measured in PRBC after opsonizion with 
fresh serum by FACS analysis.  For details, see Materials and Methods. The level of membrane bound IgG of 
DHA/R406 treated PRBC is expressed as relative mean fluorescence intensity (MFI) after setting the value for 
untreated PRBC one for each donor. Mean values ±SD (N=8) (** P<0,05) 
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4.7 Synergistic effect of DHA and R406 combination 
on membrane bound autologous IgG and C3c. 
 
The promising results obtained by cytofluorimetry on increased C3c and IgG binding 
to the membrane of parasitized RBC after treatment either with DHA or R406, led us 
to investigate the combination of DHA and R406 by flow cytometry.  
Figure 28 shows a synergistic effect of R406 for DHA-elicited IgG- and C3c- binding 
to the membrane. The results show that membrane-bound autologous IgG and C3c were 
remarkably higher after the combined treatment with DHA-R406 vs. R406 alone, 
confirming the synergism of both substances observed in phagocytosis efficacy.  
More precisely, the level of membrane bound IgG increases by 45% and 37% after 
incubation with the combination of 0.5 uM DHA with 0.5 uM R406 in comparison with 
0.5 uM DHA or 0.5 uM R406 alone, respectively. 
Very interesting is the substantial increase of DHA-elicited C3c deposits on the 
membrane by an additional supplementation of 0.5 uM R406 to PRBC. I observed: 
While 0.1uM DHA increased the C3c level found in untreated PRBC by 10 %, the 
additional supplementation with 0.5 uM R406 rose the level by 38%, hence 28% due to 
the Syk- inhibitor. Even in PRBC treated with high concentrations of DHA (0.5 uM) 
R406 treatment increased the complement binding by further 34 %. From these 
observations it is possible to hypothesize that i) R406 leads to an activation of DHA 
favoring the binding of IgG and C3c to antigenic receptors on the surface of the red 
blood cell and consequently triggering the phagocytosis signals or ii) DHA and R406 
act simultaneously triggering a synergistic action in the binding of IgG and C3c to the 
surface of red blood cells. 
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A) 
 
 
B) 
 
 
Figure 28: Synergistic action of DHA and R406 combination on membrane bound autologous IgG and 
C3c. The level of membrane bound IgG (panel A) and C3c (panel B) after 5 hours of incubation with DHA and 
R406 comabination. PRBC were opsonized with fresh serum and subjected to FACS analysis. I For details, see 
Materials and Methods. The level of membrane bound IgG of PRBC- DHA/R406 treated were expressed as  
normalized mean fluorescence after setting the value for control one for each donor. 
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4.8 Morphological changes induced by Syk inhibitor 
(R406), DHA and after their combination.  
 
In this embodiment, synchronized cultures were treated with DHA as a single agent and 
in combination with Syk inhibitors (R406). Selected PRBC were presented after 6 and 
18 hours of treatment. The most striking morphological alterations were observed in 
fixed blood smears of parasite culture treated with Syk inhibitor in combination with 
DHA after 18 hours, in comparison to the control cultures. A modest reduction in their 
size was observed at 6 hours of incubation, perhaps suggesting slower parasite growth 
(cells cycle delay). At 18 hours of incubation, there was evidence of a marked reduction 
in parasite growth (smaller size) (fig. 30). 
 
 
Figure 30: Parasite morphology after 18 hours of drug treatment. Plasmodium falciparum Palo alto parasite 
cultures were incubated with 0.5 uM DHA as a single agent and in combination with 0.5 uM R406. Giemsa-
stained of blood smears were prepared and viewed by microscopy using a 100x objective.  
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4.9 Immunoprecipitation (IP) of Band 3 protein from 
R406- treated PRBC 
 
After observing, by flow cytometry, differences between treated and untreated PRBC 
on the binding of IgG and complement factor C3c on the red blood cells membranes, I 
assessed the level of band 3 protein and IgG level by immunoprecipitation with protein 
G and subsequent western blot. I observed that, concentrations of R406 0,1/0,5 and 1 
uM leads (as shown previously section) an increase of the level of membrane bound 
IgG, suggesting that R406 cause a modification on the RBC membrane, favoring 
recognition antigen-antibody complex and consequently, favoring erytrophagocytosis 
by human monocyte. To confirm the results seen by flow cytometry and to better 
understand the hypothetical mechanism of R406, I used IP assay to show the level of 
IgG-bound band 3 protein and IgG level on erythrocyte membrane of PRBC after 
treatment with R406 1uM. The results in figure 31 show that there is an increase of 
Band 3 and IgG level after treatment with R406 1uM versus control. After densitometry 
analysis the level of Bd 3 is increased by 82% after treatment with R406 1uM. The level 
of IgG bound on erythrocyte ghost membrane are increased by 32% after treatment with 
R406 1uM.  
 
Figure 31: Level of Band 3 protein and IgG, bound to erythrocyte membrane (ghost) evaluated after   
immunoprecipitation of proteins linked with IgG. The level of Band 3 protein (panel left) and IgG (panel 
right) after 5 hours of incubation with 1 uM R406. PRBC were opsonized with fresh serum. RBC membranes 
were prepared , proteins extracted and subjected to IP with protein G Sepharose. For details, see Materials and 
Methods.  
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5. Discussion 
 
Currently, the best treatment of Plasmodium falciparum malaria is the artemisinin-
based combination therapy (ACT), in which derivates of artemisinin are combined with 
a partner antimalarial drug from another class. It has been demonstrated that Syk 
inhibitors suppress the capability of the parasites to complete their life cycle and to 
infect new erythrocytes. Thus, it’s possible to consider Syk inhibitors a new promising 
class of antimalarial drugs. The antiparasitic activity of Syk inhibitors is based on the 
inhibition of microparticle shedding that removes band 3 protein bound hemichromes 
from the RBC membrane. As band 3 protein clusters in RBC membranes bind auto anti-
band 3 antibodies I hypothesized  that Syk inhibitors may provoke  an  elevated 
phagocytic removal of pRBC.  
The purpose of this work was to investigate the combination activity of Syk inhibitor 
with ART. In particular, I investigated the role of immune cells on clearance of 
P.falciparum infected RBC before and after treatment with DHA, R406 alone and both 
combination.  
The cell mediated response in nonimmune malaria patients involves circulating and 
tissue resident phagocytes. The phagocytic system has the capacity to control 
parasitemia or to annihilate it altogether. Phagocytic cells recognizes parasitized RBC 
as nonself cells and attack them by the same response adopted against any invader.  
We think that the identification of novel drug, capable of promoting the role of the 
immune system in the clearance of the parasite, represents a goal to counteract 
artemisinin resistance.  
In the present study, I show that human adherent monocytes are able to phagocyte anti-
D IgG-opsonized RBC and P. falciparum infected red blood cells at different life cycle 
stage. As expected, the highest phagocytosis levels were observed with monocytes fed 
with anti-D IgG-opsonized RBC and malaria pigment hemozoin, the latter being 25 
times higher than phagocytosis values with NPRBC. Also mature blood stages 
(trophozoites) were avidly phagocytosed (9.2 times above NPRBC values), while young 
staged ring-PRBC show rather low phagocytosis rates just 3-fold higher than those with 
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NPRBC. Note, that the measurable phagocytosis level of NPRBC might be an 
overestimation  due to the homologous phagocytosis model, where monocytes and RBC 
derived from different donors. Nonetheless, phagocytosis of ring-PRBC remains clearly 
inferior the later stage trophozoite phagocytosis by about 70%. This differences were 
described previously and are also due to profound host cell membrane changes elicited 
by the growing parasite not before late stages, such as the introduction of parasite 
antigens into the RBC membrane.  The avid phagocytosis in vivo of trophozoites results 
in the uptake and consequent persistence of malarial pigment hemozoin in the 
phagocytes. There is a huge body of literature that describes the immune-modulatory 
consequences of the presence of this non-degradable material in the lysosome of 
monocytes, macrophages and dendritic cells. Hemozoin persistence in monocytes leads 
to the functional incapacitation of the phagocyte, which is no longer able to perform  
further phagocytic cycles, oxidative burs, migration and differentiation to macrophages 
and dendritic cells or function as nursery cell in erythropoiesis . On the other, hand 
hemozoin elicits an immediate strong release of ROS and pro-inflammatory cytokines, 
such as TNF.  Both, immune-suppressive and inflammatory actions of hemozoin had 
been associated with malaria patho-mechanisms and severe malaria. Thus the 
stimulation of phagocytosis of young, ring-stage PRBC by Syk inhibitors would be 
beneficial.    
Firstly I had to rule out concerns regarding the effects of Syk inhibitors on phagocyte 
function as to the known  regulatory role of Syk in phagocytosis and oxidative burst.   
As assumed, I saw that R406 inhibits the phagocytosis of anti-D IgG-opsonized RBC 
by human adherent monocytes in a dose dependent manner.  A decrease of phagocytic 
activity was observed when monocytes were pre-incubated with increasing R406 
concentrations, with a substantial inhibition of about 70 % at 0.5 uM. Though, in 
presence of IFN-γ, the agonist that strengthens the Fc- dependent phagocytosis, 
inhibition by Syk inhibitor R406 was just 25 % at this concentration. Lower 
concentrations of the inhibitor did not significantly inhibit at all. The presence of 
interferon meets the malaria condition where the blood level of this cytokine is 
increased due to activated lymphocytes. Calculating the concentration that a 
monocyte/macrophage might see in vivo after a single dose administration of R406, 
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bearing in mind the pharmacokinetics the value remains well below 0.5 uM. Thus a 
direct effect of Syk inhibitors on phagocytes might be insignificant in vivo. 
Surprisingly we did not see an increase of phagocytosis by IFN-gamma alone, which 
had been the case if Fc-receptor dependent phagocytosis would mainly contribute to the 
overall phagocytosis. One might argue that phagocytes were already primed without 
exogenous treatment of   with interferon as phagocytosis was performed the second day 
after blood donation and buffy coats were stored overnight.  These conditions may mask 
he increase in FcR-mediated phagocytosis induced by IFN-γ.  
I further show that R406 lead a decrease of PMA-elicited oxidative burst with increasing 
R406 concentrations. These data suggest that some essential functions of monocyte, 
like phagocytic activity and to produce PMA-elicited oxidative burst, are incapacitated 
after treatment with R406.  
To avoid the incapacitation of monocyte functions by Syk-inhibitors phagocytosis 
experiments with PRBC were designed that monocytes were not exposed to free R406.   
To evaluate the effect of Syk inhibitor on phagocytosis of P. falciparum infected red 
blood cells, different concentrations of R406 (0.1 – 0.5 – 1 uM) have been tested in 
combination with DHA. I show that Syk inhibitors such as R406 used in combination 
with DHA exerts a marked synergic effect on phagocytosis of P. falciparum infected 
red blood cells suggesting a novel mechanism of action of this promising antimalarial 
drug.  
In fact, it should be noticed that at 0.5 uM concentration R406 show measurable effect 
on phagocytosis of the parasite and when used in combination with DHA 0.1 uM, it 
potentiates the activation seen with artemisinin and leads to a significant increase of 
phagocytosis level. Not significant increase was detectable at lower concentrations of 
R406 (0.1 uM) while higher concentration of R406 (1uM), leads to an impairment of 
phagocytosis. Consistent with the effect of R406 on monocyte activity, it is possible 
that at the 1uM concentration the phagocytic activity of the monocyte is strongly 
compromised or, considering its toxicity, concentration higher 0.5 uM leads to red blood 
cells death. To evaluate the mechanism by which DHA and R406 can lead to an increase 
of phagocytosis I try to identify the role played by IgG and complement system 
activation, respectively, on enhanced phagocytosis. IgG and C3c bound to the host cell 
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membrane has been measured by flow cytometry in presence of increasing 
concentration of R406, DHA and after their combination. As we know from the 
literature, the malarial parasite induces an oxidative stress on its host erythrocyte and, 
despite the antioxidant defense systems, oxidative damage is observed on the 
erythrocyte membrane with a consequent increase in hemicromes. These alterations 
lead to the deposition of autologous IgG specific for Band 3 protein with a subsequent 
deposition of C3c fragments of the complement. All these processes modify the surface 
of the infected erythrocyte allowing the recognition by the phagocytes. Deposition of 
autologous IgG and C3c fragments on the erythrocyte membrane was increased by 26% 
and 29% respectively for IgG and C3c after incubation with 0.5 uM R406. But the very 
interesting data regards the increased of membrane bound IgG and C3c after 
combination DHA 0.5 uM and R406 0.5 uM, valued for 37% and 28% respectively for 
IgG and C3c.  
These significant data obtained by flow cytometry are comforting about the role of Syk 
inhibitor on phagocytosis of parasites, considering that opsonization with pooled human 
serum (in presence of complement) may mask the increase in FcR-mediated 
phagocytosis.  
Data of increased phagocytosis by monocytes and data about increased deposition of 
IgG and C3c on the red blood cell membrane after treatment of PRBC with DHA and 
R406 suggest an important role of Syk Inhibitor in parasite clearance.  
The analysis of the role of Syk inhibitor on the immune system gains more emphasis 
thanks to recent studies showing that R406 leads to an inhibition of the growth of the 
parasite. In fact, as demonstrated by studies in our laboratory, younger stage parasite 
are rapidly digested by monocytes and the process can be repeated without loss of 
efficiency by phagocytes. As showed by Schwarzer et al, phagocytosis of more mature 
stages of the parasite inhibits the ability of monocytes to repeat the phagocytosis process 
and to express class II membrane antigens after IFN-γ stimulation and to correctly 
present antigens. 
Observing the data obtained with the flow cytometer, we hypothesized that R406 may 
induce modification on the red blood cells membrane. This idea has been supported by 
assessed the level of band 3 protein, flagged by IgG and the IgG level by 
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immunoprecipitation. I show that, R406 concentrations of 0,1- 1 uM leads to an increase 
of the level of membrane bound IgG, confirming that R406 cause a modification on the 
RBC membrane, favoring recognition antigen-antibody complex and consequently, 
favoring erytrophagocytosis by human monocyte. 
 
Concluding, our research group demonstrated that Syk kinase inhibitors do not promote 
oxidative toxicity to healthy RBCs as they do not produce appreciable amounts of 
hemichromes. Since some Syk kinase inhibitors can be taken daily with minimal side 
effects, we proposed that Syk kinase inhibitors could contribute measurably to the 
potencies of ACTs.  
My data support the hypothesis that Syk inhibitors are a promising class of antimalarial 
drugs that can suppress parasitemia by increasing also the antiparasitic immune defense. 
Particularly, R406 should not lead to the selection of resistant strains, as it targets host 
cell molecules and will likely avoid immunosuppressive effects of hemozoin due to the 
anticipated phagocytosis of Ring stage-PRBC. Therefore, Syk inhibitors may represent 
a strategic partner drug for artemisinin therapies for counteracting artemisinin 
resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
  99 
 
6. References 
 
1. Report WHO (World Health Organization) 2018 
2. Report WHO (World Health Organization) 2017 
3. Manirakiza, A., Serdouma, E., Ngbalé, R. N., Moussa, S., Gondjé, S., Degana, R. M., Sepou, 
A. (2017). A brief review on features of falciparum malaria during preg- nancy. Journal of 
Public Health in Africa 2017, 8, 27–29. 
4. Borgella S, Fievet N, Huynh BT, Ibitokou S, Hounguevou G, et al. (2013) Impact of 
Pregnancy-Associated Malaria on Infant Malaria Infection in Southern Benin. PLOS ONE 
8(11): e80624. 
5. Moya-Alvarez, V., Abellana, R., & Cot, M. (2014). Pregnancy-associated malaria and malaria in 
infants: an old problem with present consequences. Malaria Journal, 13, 271. 
6. Sharifi-mood, B. (2015). Malaria in Pregnant Women. International Journal of Infection, 2(3), 2–
3. 
7. Beeson JG, Brown GV. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite 
adhesion and antigenic variation. Cell Mol Life Sci. 2002;59(2):258-271. 
8. Lopez Del Prado GR, Hernan Garcia C, Moreno Cea L, et al. Malaria in developing countries. J 
Infect Dev Ctries. 2014;8(1):1-4. 
9. https://www.cdc.gov/malaria/about/biology/index.html 
10. Chugh, M., Sundararaman, V., Kumar, S., Reddy, V. S., & Siddiqui, W. A. (2013). Protein 
complex directs hemoglobin-to-hemozoin formation in Plasmodium falciparum. PNAS, 1– 
6. 
11. Rosenthal PJ (2011) Falcipains and other cysteine proteases of malaria parasites. Adv Exp 
Med Biol 712:30–48. 
12. Klemba M, Gluzman I, Goldberg DE (2004) A Plasmodium falciparum dipeptidyl 
aminopeptidase I participates in vacuolar hemoglobin degradation. J Biol Chem 
279(41):43000–43007. 
13. https://www.cdc.gov/malaria/about/disease.html 
14. Bartoloni, A., & Zammarchi, L. (2012). Clinical Aspects of Uncomplicated and Severe 
Malaria. Mediterranean Journal of Hematology and Infectious Diseases, 4(1), e2012026. 
15. Trampuz, A., Jereb, M., Muzlovic, I., & Prabhu, R. M. (2003). Clinical review: Severe malaria. 
Critical Care, 7(4), 315–323. 
16. Shikani, H. J., Freeman, B. D., Lisanti, M. P., Weiss, L. M., Tanowitz, H. B., & Desruisseaux, 
MS. (2012). Cerebral Malaria: We Have Come a Long Way. The American Journal of 
Pathology, 181(5), 1484–1492. 
17. Reithmeier RA, Casey JR, Kalli AC, Sansom MS, Alguel Y, Iwata S. Band 3, the human red cell 
chloride/bicarbonate anion exchanger (AE1, SLC4A1), in a structural context. Biochim Biophys 
Acta. 2016 Jul;1858(7 Pt A):1507-32. 
18. Da Neng Wan (1994). Band 3 protein: structure, flexibility and function. FEBS Lett. 1994 Jun 
6;346(1):26-31. 
19. Arakawa, T., Kobayashi-Yurugi, T., Alguel, Y., Iwanari, H., Hatae, H., Iwata, M., Iwata, S. 
(2015). Crystal structure of the anion exchanger domain of human erythrocyte band 3. 
Science, 350(6261), 680 LP-684. 
 
  100 
 
20. Iv, S. E. L., Bennett, G. V., Branton, D., Bruce, L., Delaunay, J., Discher, D., Palek, J. (2018). 
Review Article Anatomy of the red cell membrane skeleton : unanswered questions. Blood, 
127(2), 187–200. 
21. Saito, M., Watanabe-nakayama, T., Machida, S., & Osada, T. (2015). Biophysical Chemistry 
Spectrin – ankyrin interaction mechanics: A key force balance factor in the red blood cell 
membrane skeleton. Biophysical Chemistry, 200–201, 1–8. 
22. Rui, Z., Chenyu, Z., Qi, Z., & Donghai, L. I. (2013). Spectrin : Structure, function and disease. 
Science China Life Sciences, 56(12), 1076–1085. 
23. WHO. Guidelines for the treatment of Malaria. 2018. 
 
24. Cui L, Su XZ. (2009). Discovery, mechanisms of action and combination therapy of artemisinin. 
Expert Rev Anti Infect Ther. 2009 Oct;7(8):999-1013 
25. White NJ (1997). Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. 
Antimicrob. Agents Chemother, 41 (7): 1413–22. 
26. Brown, Geoff (2006). Artemisinin and a new generation of antimalarial drug. Education in 
Chemistry. Vol. 43 no. 4. Royal Society of Chemistry, pp. 97–99. 
27. Winzeler EA, Manary MJ (2014). Drug resistance genomics of the antimalarial drug artemisinin. 
Genome Biology, 15 (11): 544 
28. Cravo P, Napolitano H, Culleton R (2015). How genomics is contributing to the fight  against 
artemisinin-resistant malaria parasite. Acta Tropica, 148: 1–7. 
29. Kannan R1, Sahal D, Chauhan VS. (2002). Heme-artemisinin adducts are crucial mediators of the 
ability of artemisinin to inhibit heme polymerization. Chem Biol. 2002 Mar;9(3):321-32. 
30. Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, Liu M, Liew CX,  Lee 
YQ, Zhang J, Lu N, Lim CT, Hua ZC, Liu B, Shen HM, Tan KS, Lin Q (2015). Haem- activated 
promiscuous targeting of artemisinin in Plasmodium falciparum. Nature Communications, 
6: 10111. 
31. Woo, Soon Hyung; Parker, Michael H.; Ploypradith, Poonsakdi; Northrop, John; Posner, Gary H. 
(1998). Direct conversion of pyranose anomeric OH→F→R in the artemisinin family of 
antimalarial trioxanes. Tetrahedron Letters. 39 (12): 1533–6. 
32. Cumming JN; Ploypradith P; Posner GH (1997). Antimalarial activity of artemisinin (qinghaosu) 
and related trioxanes: mechanism(s) of action. Adv. Pharmacol. Advances in Pharmacology, 37: 
253–97. 
33. Gary H. Posner & Paul M. O’Neil (2004). Knowledge of the Proposed Chemical Mechanism of 
Action and Cytochrome P450 Metabolism of Antimalarial Trioxanes Like Artemisinin Allows 
Rational Design of New Antimalarial Peroxides. Acc. Chem. Res, 37 (6): 397–404. 
34. Zhou Y, Li W, Xiao Y (2016). Profiling of Multiple Targets of Artemisinin Activated by Hemin in 
Cancer Cell Proteome. ACS Chemical Biology, 11 (4): 882–8. 
35. World Health Organization. (2018). Artemisinin resistance and artemisinin-based combination 
therapy efficacy: status report (2018). 
36. Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O'Flaherty K, Takashima E, Langer C, Tsuboi 
T, Dondorp AM, Day NP, Dhorda M, Fairhurst RM, Lim P, Amaratunga C, Pukrittayakamee S, 
Hien TT, Htut Y, Mayxay M, Faiz MA, Beeson JG, Nosten F3, Simpson JA, White NJ, Fowkes FJ. 
Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin 
resistance in a multinational cohort. Proc Natl Acad Sci U S A. 2017 Mar 28 
  101 
 
37. Kobayashi T, Nakamura S, Taniguchi T, Yamamura H. Purification and characterization of a 
cytosolic protein-tyrosine kinase from porcine spleen. Eur J Biochem. 1990;188(3):535–40 
38. Singh, R., Masuda, E. S. & Payan, D. G. (2012). Discovery and development of spleen tyrosine 
kinase (SYK) inhibitors. J. Med. Chem, 55, 3614–3643.  
39. Pantaleo A, Ferru E, Carta F, Mannu F, Giribaldi G, Vono R, Lepedda AJ, Pippia P, Turrini F. 
Analysis of changes in tyrosine and serine phosphorylation of red cell membrane proteins 
induced by P. falciparum growth. Proteomics. 2010 Oct;10(19):3469-79 
40. Pantaleo A, Kesely KR, Pau MC, Tsamesidis I, Schwarzer E, Skorokhod OA, Chien HD, Ponzi M, 
Bertuccini L, Low PS, Turrini FM. Syk inhibitors interfere with erythrocyte membrane 
modification during P falciparum growth and suppress parasite egress. Blood. 2017 Aug 
24;130(8):1031-1040 
41. Kesely KR, Pantaleo A, Turrini FM, Olupot-Olupot P, Low PS. Inhibition of an Erythrocyte 
Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates 
Parasitemia. PLoS One. 2016; 11(10) 
42. Billett HH. Syk TKIs "strengthen" RBCs against malaria. Blood. 2017 Aug 24;130(8):960-961.  
43. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, 
Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, 
Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling 
and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 
Dec;319(3):998-1008 
44. Michael E. Weinblatt, Mark C. Genovese, Meilien Ho, Sally Hollis Krystyna Rosiak- 
Jedrychowicz, Arthur Kavanaugh, David S. Millson, Gustavo Leon, Désirée van der Heijde 
(2014). Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid 
Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, 
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. 
Arthritis Rheumatol, 66(12):3255-64. 
45. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-
label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of 
Syk. Blood. 2009 Apr 2;113(14):3154-60 
46. Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy – 
Full Text View – ClinicalTrials.gov. Retrieved 2016-11-19. 
47. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo 
J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp 
MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-
Hodgkin Lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578-85 
48. Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, 
Hollenbach SJ, Phillips DR, Sinha U. Specific Inhibition of Spleen Tyrosine Kinase Suppresses 
Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis. J 
Pharmacol Exp Ther. 2012 Feb;340(2):350-9. 
49. Spurgeon, S. E., Coffey, G., Fletcher, L. B., Burke, R., Tyner, J. W., Druker, B. J., Loriaux, M. M. 
(2013). The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function 
In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. 
Journal of Pharmacology and Experimental Therapeutics, 344(2) 378–387. 
50. White NJ. Malaria parasite clearance. Malar J. 2017; 16: 194. 
  102 
 
51. Joice R, Frantzreb C, Pradham A, Seydel KB, Kamiza S, Wirth DF, et al. Evidence for spleen 
dysfunction in malaria-HIV co-infection in a subset of pediatric patients. Mod Pathol. 2016 
Apr;29(4):381-90 
52. Buffet PA, Safeukui I, Milon G, Mercereau-Puijalon O, David PH. Retention of erythrocytes in 
the spleen: a double-edged process in human malaria. Curr Opin Hematol. 2009;16:157–164 
53. Ndour PA, Lopera-Mesa TM, Diakité SA, Chiang S, Mouri O, Roussel C, Jauréguiberry S, Biligui S, 
Kendjo E, Claessens A, Ciceron L, Mazier D, Thellier M9, Diakité M, Fairhurst RM, Buffet PA. 
Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children 
treated with artesunate for malaria. J Infect Dis. 2015 Jan 15;211(2):290-7. 
54. Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of 
drug effectiveness and resistance? Antimicrob Agents Chemother. 2015;59:6428–6436.  
 
55. Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of 
normally senescent and pathological human erythrocytes. Cell Physiol Biochem. 2005;16:133–
146 
56. Pantaleo A, Giribaldi G, Mannu F, Arese P, Turrini F. Naturally occurring anti-band 3 antibodies 
and red blood cell removal under physiological and pathological conditions. Autoimmun Rev. 
2008 Jun;7(6):457-62 
57. https://www.cdc.gov/malaria/about/biology/human_factors.html 
 
58. Uhlemann A-C, Fidock DA. 2012. Loss of malarial susceptibility to artemisinin in Thailand. Lancet 
379:1928–1930 
59. Fairhurst RM, Nayyar GML, Breman JG, Hallett R, Vennerstrom JL, Duong S, Ringwald P, Wellems 
TE, Plowe CV, Dondorp AM. 2012. Artemisinin-resistant malaria: research challenges, 
opportunities, and public health implications. Am J Trop Med Hyg 87:231–241 
60. Chihara K, Kato Y, Yoshiki H, Takeuchi K, Fujieda S, Sada K. Syk-dependent tyrosine 
phosphorylation of 3BP2 is required for optimal FcRγ-mediated phagocytosis and chemokine 
expression in U937 cells. Sci Rep. 2017 Sep 13;7(1):11480 
61. Wang Z, Zhou S, Sun C, Lei T, Peng J, Li W, Ding P, Lu J, Zhao Y. Interferon-γ inhibits nonopsonized 
phagocytosis of macrophages via an mTORC1-c/EBPβ pathway. J Innate Immun. 2015;7(2):165-
76 
62. Darwich L1, Coma G, Peña R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, 
Andreo F, Parkhouse RM, Bofill M. Secretion of interferon-gamma by human macrophages 
demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. 
Immunology. 2009 Mar;126(3):386-93 
63. Kidd BA, Wroblewska A, Boland MR, Agudo J, Merad M, Tatonetti NP, Brown BD, Dudley JT. 
Mapping the effects of drugs on the immune system. Nat Biotechnol. 2016 Jan;34(1):47-54 
64. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ. Mechanism 
of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93(3):198-208. 
65. Prato M, Gallo V, Giribaldi G, Aldieri E, Arese P. Role of the NF-κB transcription pathway in the 
haemozoin- and 15-HETE-mediated activation of matrix metalloproteinase-9 in human 
adherent monocytes. Cell Microbiol. 2010 Dec;12(12):1780-91 
  103 
 
66. Lin PY, Feng ZM, Pan JQ, Zhang D, Xiao LY. Effects of artesunate on immune function in mice. 
Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):441-4. 
67. Alberola-Ila J, Takaki S, Kerner JD, Perlmutter RM. Differential signaling by lymphocyte antigen 
receptors. Annu Rev Immunol. 1997;15:125-54. 
68. Schwarzer E, Turrini F, Ulliers D, Giribaldi G, Ginsburg H, Arese P. Impairment of macrophage 
functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial 
pigment. J Exp Med. 1992 Oct 1;176(4):1033-41. 
69. Skorokhod O, Schwarzer E, Grune T, Arese P. Role of 4-hydroxynonenal in the hemozoin-
mediated inhibition of differentiation of human monocytes to dendritic cells induced by GM-
CSF/IL-4. Biofactors. 2005;24(1-4):283-9. 
70. Uyoga S, Skorokhod OA, Opiyo M, Orori EN, Williams TN, Arese P, Schwarzer E. Transfer of 4-
hydroxynonenal from parasitized to non-parasitized erythrocytes in rosettes. Proposed role in 
severe malaria anemia. Br J Haematol. 2012 Apr;157(1):116-24 
71. Turrini F, Mannu F, Arese P, Yuan J, Low PS. Characterization of the autologous antibodies that 
opsonize erythrocytes with clustered integral membrane proteins. Blood. 1993 Jun 
1;81(11):3146-52. 
72. Schwarzer E, Turrini F, Arese P. A luminescence method for the quantitative determination of 
phagocytosis of erythrocytes, of malaria-parasitized erythrocytes and of malarial pigment. Br J 
Haematol. 1994 Dec;88(4):740-5. 
73. Turrini F, Ginsburg H, Bussolino F, Pescarmona GP, Serra MV, Arese P. Phagocytosis of 
Plasmodium falciparum-infected human red blood cells by human monocytes: involvement of 
immune and nonimmune determinants and dependence on parasite developmental stage.  
Blood. 1992 Aug 1;80(3):801-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  104 
 
Acknowledgements 
 
My sincere thanks go to my supervisor Prof. Francesco Michelangelo Turrini, for his 
guidance, support, suggestions and to convey me part of his experience. The special 
thanks and my gratitude go to my co-supervisor Prof. Evelin Schwarzer. She has been 
my special mentor, I have to thanks her for great support, humanity, encouragement in 
this study. Thanks also for her immense patience, for her indispensable advice, for the 
knowledge transmitted throughout the course of PhD and during the writing of thesis. 
In addition, a sincere thanks to Prof. Lucia De Franceschi, coordinator of the PhD 
programme in Biomolecular Medicine.  
I wish to express my grateful to all my colleagues from University of Verona. Special 
thanks to Dr. Rosalba La Grotta, Dr. Elena Valente, Dr. Daniela Ulliers from University 
of Turin, for cooperation, help and friendship. Their presence has been fundamental for 
this work.  
Thanks also to other colleagues and many students who in these years, regardless of this 
work enriched, intellectually and humanly, my daily life professional.  
Thanks to Costanzo Costamagna, for the time spent with him, for his support in work 
and life, for his great friendship.  
Finally, I am grateful to all the people who taught me something more during my PhD 
course taking part in my scientific growth. 
I dedicate this thesis to Laura, my partner in life, who has been a constant source of 
support and encouragement during my PhD. Thanks also for having been able to rely on 
her in moments not only joy but also stress in my PhD course. 
This work is also dedicated to all my large family that loves me unconditionally and 
always provides wise advice for my life. 
 
 
 
 
 
 
 
 
 
 
  105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
